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Warfarin has been the most commonly used oral anticoagulant to 
prevent cardiovascular diseases. Though it is widely used, warfarin 
presents a major concern: out-of-range International Normalized Ratio 
(INR) values. However, identification and assessment of factors 
associated with INR control can help keep INRs in the therapeutic range. 
In addition to warfarin, two novel oral anticoagulants (i.e., dabigatran and 
rivaroxaban) have recently been approved for the prevention of stroke in 
patients with atrial fibrillation (AF) in Singapore. As the costs of 
dabigatran and rivaroxaban are higher than that of warfarin, their cost-
effectiveness compared with warfarin needs to be evaluated. Therefore, 
this project had two objectives: 1) to assess patients’ medication 
adherence, knowledge, satisfaction and concerns regarding warfarin 
therapy, and their associations with INR control, and 2) to assess the cost-
effectiveness of dabigatran and rivaroxaban compared with warfarin in 
patients with AF, using local utilities. 
 
First, the psychometric properties of the 8-item Morisky Medication 
Adherence Scale (MMAS) were assessed in patients taking warfarin in 
Singapore, as the scale needed to be validated before being applied to a 
specific patient population. It was found that the scale had moderate 
reliability (Cronbach’s alpha = 0.56). Good criterion-related validity was 
found, which was assessed via the association of MMAS scores and 
medication refill adherence (MRA) (rs = 0.17; p = 0.04). Confirmatory 
factor analysis indicated that the 8-item MMAS was unidimensional (root 
mean square error of approximation = 0.03). All but one hypothesis were 
fulfilled.   
 
Second, three medication adherence measures, i.e., the 8-item MMAS, 
the visual analogue scale (VAS) and the MRA were compared to identify 
the most suitable medication adherence measure in patients taking 
warfarin. The MRA was found to be associated with most of the INR 
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measures, including the percentage of time in the therapeutic range in the 
past 3 months and past 2 weeks (rs = 0.21 and 0.16; p = 0.01 and 0.045, 
respectively), and the percentage of INRs within the therapeutic range in 
the past 2 weeks (p = 0.03). Therefore, it might be a more suitable 
measure of warfarin adherence than the MMAS and the VAS. 
 
Third, MRA, patient-reported knowledge, satisfaction and concerns 
regarding warfarin therapy and their associations with INR control were 
assessed. It was found that patients generally had high medication 
adherence (mean ± SD = 92.0 ± 16.8%), moderate knowledge (6.6 ± 2.3), 
moderate satisfaction (21.2 ± 3.6) and few concerns (median = 1). 
Moreover, patients with better knowledge, higher warfarin adherence, 
higher satisfaction and fewer concerns were more likely to have better 
INR control (p = 0.003, 0.009, 0.02 and 0.048, respectively). 
 
Fourth, to obtain the local utilities for anticoagulant-related health 
states (e.g., ischemic stroke), the standard gamble technique and the VAS 
were used to assess patient-reported utilities in patients taking warfarin. 
It was found that ischemic stroke (-0.01 ± 0.53) and intracranial 
hemorrhage (ICH) (-0.09 ± 0.51) had a significant impact on patients’ 
health-related quality of life with a large variation in individual utilities. 
The findings of this study can be used in cost-utility analyses of oral 
anticoagulants. 
 
Lastly, the cost-utility of dabigatran and rivaroxaban compared with 
warfarin in patients with AF in Singapore was evaluated. A Markov model 
was used with monthly cycles and a life-long time horizon. A healthcare 
payer perspective was adapted. The base-case analysis found that 
rivaroxaban was a cost-effective therapy compared with warfarin, using a 
willingness-to-pay (WTP) threshold of Singapore dollar (SGD) 65,000, i.e., 
US dollar (USD) 51,842, per quality-adjusted life year (QALY). The 
incremental cost-effectiveness ratio (ICER) was SGD 36,231.02 (USD 
28,975.54) per QALY. The ICER of dabigatran 150 mg versus warfarin was 
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SGD 254,492.45 (USD 203,528.81) per QALY. Therefore, rivaroxaban had 
extended dominance over dabigatran 150 mg. Dabigatran 110 mg was 
dominated by warfarin. The results were confirmed in the probabilistic 
sensitivity analysis, i.e., rivaroxaban was cost-effective in 91.29% and 
98.64% of the 10,000 iterations, using a WTP threshold of SGD 65,000 
(USD 51,842) per QALY and SGD 130,000 (USD 103,685) per QALY, 
respectively. 
 
In conclusion, the major findings of this project included that 1) the 8-
item MMAS had moderate reliability and good validity in patients taking 
warfarin in Singapore; 2) the MRA might be a more suitable measure for 
warfarin adherence compared with the 8-item MMAS and VAS; 3) patients 
with better knowledge, higher warfarin adherence, higher satisfaction 
and fewer concerns were more likely to have better INR control; 4) the 
local utilities for ischemic stroke and ICH were low; and 5) rivaroxaban 
was cost-effective compared with warfarin in patients with AF in 
Singapore. This project provided important information on patient-
reported outcomes and the cost-effectiveness of oral anticoagulants. The 
findings of this project have paved the way for future studies that aim to 
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Chapter 1 Introduction 
 
1.1 Cardiovascular Diseases (CVDs) – Top-Ranked Cause of Mortality and 
Substantial Disease Burden 
 
CVDs are the 1st leading cause of mortality worldwide, causing 
approximately 17.3 million deaths annually and accounting for nearly 
one-third of all-cause global mortality [1]. Of these deaths, nearly 42% 
and 36% were due to coronary heart diseases and stroke, respectively [1]. 
It is estimated that deaths due to CVDs may increase to more than 23 
million by 2030, remaining the 1st-ranked cause of mortality in the world 
with the largest increase of CVD-specific mortality arising in South-East 
Asia [1, 2].  
 
In Singapore, ischemic heart diseases and stroke rank 2nd and 4th on 
the list of disease-specific causes of death and make up 52% and 36%, 
respectively, of the disease burden of CVDs as indicated by disability-
adjusted life years [3, 4]. Therefore, CVDs are the largest component 
(almost one-fifth) of the total disease burden in Singapore and account for 
34% of total years of life lost each year [4].  Furthermore, the risk of CVDs 
rises exponentially as age increases, which leads to CVDs accounting for 
one-third of the total disease burden in patients aged 65 and above [4, 5]. 
The disease burden from CVDs is likely to increase in Singapore because 
its population is aging with longer life expectancy over the past few years 
[6]. As a result, there is an urgent need for the Singapore healthcare 
system to prevent and control CVDs. 
 
1.2 Warfarin – The Cornerstone of Oral Anticoagulants 
 
1.2.1 Warfarin and Its Adverse Effects 
 
Oral anticoagulation has been used as a prophylactic measure for 
CVDs. Warfarin, a vitamin K antagonist, has been the most commonly used 
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oral anticoagulant and has remained the cornerstone of oral 
anticoagulants for more than five decades [7]. It was found that 
approximately 60% of all oral anticoagulants used were warfarin in a 
number of western and Asian countries [8, 9]. The most common 
indications of warfarin include the prevention of venous 
thromboembolism (e.g. deep vein thrombosis (DVT) and pulmonary 
embolism) and thromboembolism in patients with atrial fibrillation (AF) 
and heart valve replacement, followed by acute myocardial infarction (MI) 
in patients with peripheral vascular diseases, which may cause stroke and 
vascular death if untreated [10, 11]. Without prophylaxis, the incidences 
of DVT and pulmonary embolism can rise dramatically, leading to hospital 
deaths [12]. Cardiogenic embolism from AF is similarly threatening, 
subjecting patients to an almost five-fold increased risk of ischemic stroke 
and contributing to one-fifth incidences of ischemic stroke [5, 13].  
 
Warfarin can prevent systemic thromboembolism and consequently 
reduce the mortality rate. Clinical effects of warfarin can be reflected by 
patients’ International Normalized Ratio (INR) values, which is a 
standardized reliable measure of blood coagulation converted from the 
prothrombin time (PT) ratio, i.e., INR = (patient PT / mean normal PT)ISI, 
where mean normal PT denotes the mean PT from healthy controls, and 
ISI denotes the international sensitivity index that reflects the 
responsiveness of a given thromboplastin to the reduction of the vitamin 
K-dependent coagulation factors compared to the primary World Health 
Organization international reference preparations [7]. The most 
commonly used measure of INR control is the time in the therapeutic 
range (TTR), which can be calculated by the fraction of INR values or the 
Rosendaal’s linear interpolation method [7]. Other measures that have 
been used in published literature include the time out of the therapeutic 
INR range, the percentage of out-of-range INRs, and the time to the first 
therapeutic or supratherapeutic INR [14, 15]. Usually the normal 
therapeutic range of INR is from 2.0 to 3.0 and the range varies depending 




Although warfarin can yield positive clinical results, its benefits are 
often achieved at the cost of an increased risk of adverse effects [16]. The 
narrow therapeutic range of warfarin and the considerable variability in 
inter-individual responses to warfarin have led to the occurrences of out-
of-range INRs in clinical practice [7]. Almost one-third of INRs in patients 
treated with warfarin are either below or above the therapeutic range [17, 
18]. Patients with subtherapeutic and supratherapeutic INRs are at an 
increased risk of thromboembolism and hemorrhage, respectively [16, 19, 
20]. In other words, subtherapeutic INRs are associated with a higher risk 
of thromboembolism, ischemic stroke and consequent death [19, 20], 
while supratherapeutic INRs can lead to warfarin-induced hemorrhage, 
which is the most common adverse effect of warfarin and can cause 
different levels of disabilities or even death [19, 21]. The site of warfarin-
induced hemorrhage can be intracranial (e.g., hemorrhagic stroke) or 
extracranial (e.g., hematuria and gastrointestinal bleedings) [21, 22]. As a 
result, it is crucial to keep patients’ INRs in the therapeutic range when 
they are taking warfarin.  
 
1.2.2 Factors Affecting INR Control 
 
A number of factors can lead to out-of-range INRs. Risk factors of out-
of-range INRs can be either environmental or genetic and can lead to the 
incidence of therapeutic failure or warfarin-induced hemorrhage during 
both the initiation and maintenance periods of warfarin therapy [23-25]. 
Some factors are inherent, such as genetic variants, co-morbidities and 
age [23-26], while others are acquired, such as medication adherence and 
knowledge regarding warfarin therapy, and can be controlled via patients’ 
behavior. To improve INR control, it is important to identify and assess 
these associated factors. 
 




One of the acquired factors affecting INR control is medication 
adherence. Adherence to warfarin therapy as prescribed by physicians 
can prevent the inadequate or excessive anticoagulation that can lead to 
out-of-range INRs and subsequent complications [17, 27-29]. As such, it is 
important to assess patients’ medication adherence to warfarin and 
identify and address concerns with taking warfarin in order to improve 
INR control. 
 
Measures to assess medication adherence can be divided into direct 
and indirect methods [30]. The defining characteristic that distinguishes 
direct and indirect methods is whether medication adherence can be 
observed directly. Direct methods (e.g., direct observation of patients’ 
medication-taking behavior, or the measurement of concentrations of a 
drug or its metabolite in blood or urine) allow medication adherence to 
be observed directly. Indirect methods, such as patient-reported 
questionnaires and pharmacy refill rates, have been more frequently used 
in real practice than direct methods because they are less expensive and 
less invasive [30]. Among a number of patient-reported measures of 
medication adherence, the 4-item Morisky-Green-Levine Medication 
Adherence Scale is one of the most commonly used patient-reported 
questionnaires to assess patients’ medication adherence to long-term 
therapies [31]. The scale demonstrated good concurrent and predictive 
validity in patients with hypertension. However, the psychometric 
properties of the scale had been assessed in patients with Type 2 diabetes 
mellitus in Singapore, and it was found that the construct validity of the 
scale was less than satisfactory [32]. Therefore, an alternative patient-
reported questionnaire with good psychometric properties is needed to 
assess patients’ medication adherence in Singapore. 
 
The 8-item Morisky Medication Adherence Scale (MMAS) is a patient-
reported questionnaire that has been recently developed based on the 4-
item MMAS [33]. The psychometric properties of the scale have been 
found to be better than those of the 4-item version [31, 33]. However, its 
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psychometric properties have not been assessed in patients taking 
anticoagulants in Asian population. Psychometric evaluation is important, 
as it evaluates if a scale can generate reliable and valid results [34]. In 
addition, as psychometric properties of a scale vary in different 
populations [33, 35, 36], they need to be assessed before the scale is 
applied to a specific group of patients. Therefore, the psychometric 
properties of the 8-item MMAS need to be assessed in patients taking 
warfarin in Singapore. 
 
Another patient-reported measure of medication adherence is the 
100-point visual analogue scale (VAS). The scale assesses patients’ 
medication adherence by asking them to rate their medication adherence 
on a percentile scale anchored by 100 and 0 at the high and low ends of 
the scale, respectively. As it has only one question, it is easy to 
incorporate into a clinic visit. 
 
In addition to patient-reported measures, medication adherence 
measures that incorporate pharmacy administrative data are also 
commonly used. These include the continuous measure of medication 
acquisition, continuous measure of medication gaps, and the calculation 
of medication refill adherence (MRA). Among these various measures, 
MRA requires the least amount of data and the fewest calculations [37]. 
Therefore, it could be the most feasible measure that uses pharmacy 
administrative data, given the availability of data and time constraints.  
 
Although the 8-item MMAS, the VAS and the MRA all have their 
advantages for their application in real practice, it remains unknown 
which one is the most suitable for the assessment of medication 
adherence to warfarin in Singapore. The selection of medication 
adherence measures is important, as they need to be specifically chosen 
for the population and medication in question. Therefore, it is important 
to compare these three measures to identify the most suitable measure 




1.2.2.2 Assessment of Knowledge, Satisfaction and Concerns regarding 
Warfarin Therapy 
 
Other factors that can affect INR control include patients’ knowledge, 
satisfaction and concerns regarding warfarin therapy, which can also 
affect patients’ medication adherence. A few published studies assessed 
patients’ knowledge of warfarin therapy regarding warfarin 
administration (e.g., color and number of warfarin tablets taken every 
day), adverse effects of warfarin (e.g., bleedings), warfarin-drug 
interactions (e.g., impact of herbal medicines on warfarin therapy), and 
warfarin-diet interactions (e.g., impact of food containing vitamin k on 
warfarin therapy) [38-44]. It has been found that patients with better 
warfarin knowledge are more likely to have good INR control [43]. 
Identification of knowledge deficits can help healthcare providers develop 
patient-targeted education and highlight the importance of taking 
warfarin in order to improve medication adherence and INR control. 
Similarly, identification of concerns and deficits in patients’ satisfaction 
with warfarin therapy may help healthcare providers improve current 
anticoagulation services, which may also lead to better medication 
adherence and INR control. Although a number of studies assessed 
patients’ satisfaction with anticoagulation services and concerns 
regarding warfarin therapy [41, 45-51], none has examined the 
association of patients’ satisfaction and concerns with their medication 
adherence and INR control. Moreover, none of these studies were 
conducted in Singapore. Therefore, it is important to assess patients’ 
knowledge, satisfaction and concerns regarding warfarin therapy and 





1.3 Alternatives to Warfarin – Two Novel Oral Anticoagulants  
 
1.3.1 Clinical Outcomes of Dabigatran and Rivaroxaban 
 
In addition to warfarin, two novel oral anticoagulants have recently 
been approved for the prevention of stroke in patients with AF in 
Singapore. One of them is dabigatran, which is a direct thrombin inhibitor 
[52]. It is administered in the form of its prodrug, i.e., dabigatran etexilate, 
which can be rapidly absorbed and converted to the active form. The 
commonly prescribed dose regimens of dabigtran are 150 mg and 110 mg 
twice daily. The Randomized Evaluation of Long-Term Anticoagulation 
Therapy (RE-LY) trial was a randomized trial designed to compare the 
efficacy and safety of the two fixed doses of dabigatran administered in a 
blinded manner with warfarin administered in an open-label manner in 
patients with AF [53]. In the RE-LY trial, higher proportions of dyspepsia 
were found in patients taking dabigatran 150 mg (n = 707, 11.8%) and 
110 mg (n = 688, 11.3%) than warfarin (n = 348, 5.8%) [53]; however, 
dabigatran 150 mg and 110 mg were found to have better or non-inferior 
clinical efficacy in terms of risks of stroke (relative risk = 0.64 and 0.91; p 
< 0.001 and p = 0.38, respectively) and major bleeding (relative risk = 
0.93 and 0.80; p = 0.31 and 0.003, respectively), especially intracranial 
bleeding (relative risk = 0.41 and 0.30, respectively; both p < 0.001), 
compared with warfarin [54]. 
 
In addition to dabigatran, the other novel oral anticoagulant is 
rivaroxaban, which is a direct factor Xa inhibitor and has two daily doses 
of 20 mg and 15 mg [55]. The Rivaroxaban Once Daily Oral Direct Factor 
Xa Inhibition Compared with Vitamin K Antagonism for Prevention of 
Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF) study was a 
randomized double-blinded, double-dummy trial that compared the 
efficacy and safety of rivaroxaban with warfarin in patients with AF [55]. 
In this trial, it was found that rivaroxaban had better or non-inferior 
clinical efficacy in terms of risks of ischemic (hazard ratio = 0.94; p = 0.58) 
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and hemorrhagic (hazard ratio = 0.59; p = 0.02) strokes, and intracranial 
bleeding (hazard ratio = 0.67; p = 0.02) than warfarin. 
 
In addition to the aforementioned clinical outcomes of dabigatran and 
rivaroxaban, it has been found that, in contrast to warfarin, the two newer 
drugs have a rapid onset of action and predictable pharmacokinetic and 
pharmacodynamic profiles with few drug-food and drug-drug 
interactions and no need for routine coagulation monitoring [52, 56]. 
Therefore, they have been approved, as alternatives to warfarin, for the 
prevention of stroke in patients with AF in Singapore. 
 
1.3.2 Concerns of Using Dabigatran and Rivaroxaban 
 
Due to the aging populations in the past decades, demands for 
universal access to high-quality healthcare as well as the costs of 
healthcare have been rising dramatically [57, 58]. The average annual per 
capita total expenditure on healthcare has increased from Singapore 
dollar (SGD) 1,132 to 2,866, i.e., US dollar (USD) 903 to 2,286, in 
Singapore in the past a decade [59], causing a large burden on patients 
and the Singapore healthcare system. Due to the limited healthcare 
resources, it is not likely for a payer to reimburse patients or for patients 
to pay out-of-pocket for a treatment with high cost and minor health 
improvement. Dabigatran and rivaroxaban are novel drugs, which cost 
SGD 3.36 and 5.80 (i.e., USD 2.68 and 4.63) per tablet, respectively. They 
are much more expensive than warfarin, which costs SGD 0.12 (i.e., USD 
0.10) per tablet (data are from internal hospital databases, which are not 
open to the public). As such, the two novel drugs would be less likely to be 
used in clinical practice if the benefits gained are not worth the high costs. 
Therefore, to justify the value for the money, there is an urgent need for 





1.4 Pharmacoeconomics – An Approach to Evaluating Cost-Effectiveness 
of Novel Healthcare Interventions 
 
1.4.1 A Brief Introduction to Pharmacoeconomics 
 
Pharmacoeconomics has been used worldwide to evaluate the cost-
effectiveness of new healthcare interventions. The underlying theory of 
pharmacoeconomics is based on the economic, clinical and humanistic 
outcomes model, which advocates that any disease management should 
aim to achieve balanced outcomes so that gains in one outcome would not 
sacrifice the opportunity gains in other outcomes and that the overall 
gains can be maximized and optimized [60]. Pharmacoeconomics plays its 
role by identifying, measuring and comparing the costs (e.g., resource 
consumption) and consequences (e.g., clinical and humanistic outcomes) 
of different pharmaceutical products and services in order to optimize the 
allocation of limited healthcare resources. There are four types of 
pharmacoeconomic evaluations, including cost-effectiveness analysis, 
cost-benefit analysis, cost-utility analysis (CUA) and cost-minimization 
analysis, among which CUA has been recommended by the Panel on Cost-
Effectiveness in Health and Medicine as a preferred approach to reporting 
health economic evaluations because it incorporates patient-reported 
utilities such as quality-adjusted life years (QALYs) and allows for 
comparison across different diseases and health interventions [61]. 
 
1.4.2 CUA of Dabigatran and Rivoraxaban Compared with Warfarin 
 
Dabigatran and rivaroxaban are novel oral anticoagulants and have 
recently been approved for clinical use. The costs of the two drugs are 
higher than that of warfarin, and concerns have arisen from the 
justification of the value for the money, i.e., whether the effects of new 
drugs are worth the high costs. Although several economic evaluations 
have compared the cost-effectiveness of dabigatran and warfarin or that 
of rivoraxaban and warfarin, few of them were conducted in Asian 
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countries, let alone in Singapore. In addition, few studies have been 
conducted to compare the cost-effectiveness of the three anticoagulants in 
one evaluation and none of them were conducted in Asian countries. 
Therefore, it is important to evaluate the cost-effectiveness of dabigatran 
and rivaroxaban compared with warfarin in patients with AF in Singapore. 
Such an evaluation can provide useful information to government sectors 
such as the Health Technology Assessment Branch under the Ministry of 
Health, which conducts cost-effectiveness studies as well as develops 
clinical practice guidelines.    
 
1.5 Research Objectives and Questions 
 
To summarize, warfarin is essential to preventing thromboembolism, 
but the narrow therapeutic range and substantial inter-individual 
variability in dose responses have led to out-of-range INRs. An approach 
to keeping INRs within control is to identify and assess factors that affect 
INR control. Although warfarin has been approved for clinical use in 
Singapore, there is no published study that assesses patients’ concerns 
regarding and deficits in medication adherence, knowledge and 
satisfaction regarding warfarin therapy, and their associations with INR 
control. In addition, as alternatives to warfarin, dabigatran and 
rivaroxaban have recently been approved for the prevention of stroke in 
patients with AF in Singapore. However, the cost-effectiveness of these 
two novel drugs compared with warfarin in the healthcare setting in 
Singapore remains unknown. As a result, to fill in these gaps, this thesis 
study had two major objectives: 1) to assess patient-reported outcomes of 
warfarin therapy in terms of medication adherence, knowledge, 
satisfaction and concerns, and their associations with INR control in 
patients taking warfarin in Singapore; 2) to evaluate the cost-
effectiveness of dabigatran and rivaroxaban compared with warfarin in 
patients with AF in Singapore, using local utilities. Under the two major 
objectives, a few research questions were proposed. Each research 
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question is addressed in a chapter of this thesis. A list of research 




Table 1.1 Research objectives and questions 
Chapter Research question 
Objective 1  
2 
Is the 8-item MMAS a reliable and valid measure of 
medication adherence in patients taking warfarin in 
Singapore? 
3 
Among the 8-item MMAS, the VAS and the MRA, what is the 
most suitable measure of medication adherence in patients 
taking warfarin? 
4 
How are the knowledge, satisfaction and concerns 
regarding warfarin therapy associated with warfarin 
adherence and INR control in patients taking warfarin in 
Singapore? 
Objective 2  
5 
What are the patient-reported utilities for anticoagulant-
related health states in Singapore? 
6 
Are dabigatran and rivoraxaban cost-effective compared 
with warfarin in Singapore? 
INR = International Normalized Ratio, MMAS = Morisky Medication 





Chapter 2 Psychometric Properties of the 8-item MMAS in 




Thromboembolism can lead to fatal conditions if unprevented [12, 
13], and warfarin has been the oral anticoagulant most commonly used as 
a preventative measure [7, 11]. However, the drug’s narrow therapeutic 
range and considerable variability in inter-individual responses have led 
to the occurrences of out-of-range INR values in clinical practice [7]. It has 
been reported that almost one-third of INRs in patients treated with 
warfarin are either below or above the therapeutic range [17, 18], 
exposing patients to an increased risk of life-threatening 
thromboembolism and hemorrhage, respectively [16, 19, 20]. 
 
One approach to keeping INRs within the therapeutic range is to  
adhere to warfarin as prescribed by physicians [17, 27-29]. Despite the 
fact that failure to adhere to warfarin has been found to be a major 
contributor to out-of-range INRs [17, 27-29], adherence to warfarin may 
decrease over time after prescription, especially in the first two years [62]. 
Therefore, it is essential to assess patient adherence to warfarin therapy 
in order to have a better understanding of patients’ warfarin-taking 
behavior and to improve their warfarin adherence. 
 
Measures to assess medication adherence can be divided into direct 
and indirect methods, and each has its own advantages and disadvantages 
[30, 63, 64]. Direct methods, such as direct observations and biomedical 
measures, are accurate and objective; however, they are expensive, 
burdensome, and impractical for some drugs [30, 63]. On the other hand, 
patient-reported questionnaires, a type of indirect method, have been 
commonly used because they are not only inexpensive and useful in 
clinical settings, but can also provide information on reasons for patients’ 




The 8-item MMAS is a recently developed, patient-reported 
questionnaire with good validity and reliability [33], and its psychometric 
properties are better than the previous 4-item version [31]. The scale is 
simple to understand and easy to administer, and it can be easily 
incorporated into a medical visit [33]. The scale has been validated in 
patients with other chronic diseases, including hypertension [33, 65], 
diabetes mellitus [35, 36], inflammatory bowel disease [66] and 
postmenopausal osteoporosis [67]. However, none was conducted in 
patients taking anticoagulants, and only two studies were conducted in 
Asian populations [35, 36]. Therefore, the aim of this study was to assess 
the psychometric properties of the 8-item MMAS in patients taking 






A cross-sectional survey was conducted in a convenience sample of 
patients taking warfarin in an anticoagulation clinic (ACC) of the 
Singapore General Hospital (SGH) from September to December in 2011. 
The target sample size was 110 in order to have a power of 0.8 to detect a 
small correlation (r = 0.3) [68] between adherence to warfarin therapy 
and the percentage of INRs within the therapeutic range [48] at the 5% 
significance level, assuming 20% incomplete responses. This estimated 
sample size was similar to that of a previous study that validated the 8-
item MMAS [35]. 
 
Prior to survey administration, two interviewers received training in 
order to standardize the administration process. Potentially eligible 
patients were identified by referral from the ACC pharmacists.  To be 
eligible, participants had to be aged 21 years or older, on warfarin 
therapy for at least three months and able to comprehend English or 
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Chinese. Respondents who consented to participate were interviewed 
face-to-face and asked to complete the 8-item MMAS (Appendices 2.1 and 
2.2). As the original version of the 8-item MMAS was developed to assess 
adherence to high blood pressure pills as prescribed by doctors, a few 
words were modified in this study to make the MMAS suitable for the 
assessment of adherence to warfarin prescribed by doctors or 
pharmacists. For example, “high blood pressure pills” was changed to 
“warfarin/Marevan® ”, and “doctor” was changed to “doctor or 
pharmacist”. The survey questionnaire also included demographics and 
warfarin-related clinical questions (e.g. indication for warfarin). 
Participants could choose either an English or Chinese version of the 
questionnaire, depending on their language preference. The Chinese 
version of the 8-item MMAS was developed and evaluated by a panel of 
multidisciplinary and bilingual clinical experts (i.e. one clinical 
pharmacist with a master’s degree in pharmacy, three researchers with a 
Doctor of Philosophy (Ph.D.) in pharmacy and a Ph.D. candidate in 
pharmacy) based on their experience in validation and translation of 
patient-reported measures. They ensured equivalence and local 
adaptation of the two language versions in terms of content, wording, and 
cognitive levels. To be specific, the English version was translated into 
Chinese, and discrepancies in the translation were discussed and resolved 
by the Ph.D. candidate and the principal investigator, whose native 
language was Chinese. After that, the two language versions were 
independently reviewed by the clinical pharmacist and two other 
researchers, and their comments on the translation were sent to the Ph.D. 
candidate and principal investigator to finalize the Chinese version. The 
two language versions had been pilot-tested in a small group of patients 
on warfarin (n = 8) prior to the survey administration to ensure the 
questions’ clarity and readability, after which three words in the English 
version of the MMAS were modified, as patients reported confusion with 
them, i.e., “cut back” was changed to “reduced”, and “hassled” and 




Patients’ warfarin refill records for the past three months and INR 
records for the past two weeks prior to survey administration were 
retrieved from the SGH electronic databases. The three-month period was 
chosen to ensure that at least one warfarin refill record was available for 
each participant, while the two-week period was chosen to be consistent 
with the time period of the MMAS questions. Informed consent was 
obtained from survey respondents, and the study was approved by the 
Singhealth Institution Review Board. 
 
The 8-item MMAS 
 
The underlying theory of the 8-item MMAS was that medication non-
adherence could be due to patients’ behavioral and attitudinal  problems 
[33]. Therefore, the scale measured patients’ medication-taking behavior 
in terms of several factors affecting medication adherence, including 
forgetting to take medications, forgetting to bring along medications 
when travelling, not taking medications when feeling worse or better, and 
feeling hassled about sticking to medication treatment plans, etc. In order 
to increase the specificity of the questions, the observation periods of the 
questions included both non-specific and specific periods, ranging from 
the past two weeks to yesterday. The wording of seven questions was 
reversed to avoid the “yes-saying” bias, whereas the wording of one item 
was unreversed in order to prevent participants from responding in a 
specific way regardless of the content of the questions. All items but one 
used dichotomous response choices (i.e. “yes” and “no”) whereas the last 
item adopted a 5-point Likert-type response (i.e. “never”, “rarely”, 
“sometimes”, “often” and “always”). The scale scores ranged from 0 to 8, 




Internal consistency was tested by Cronbach’s alpha. A Cronbach’s  
alpha coefficient equal to or larger than 0.70 indicates high internal 
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consistency [69]. Content validity was assessed by a panel of clinical 
experts. Criterion-related validity was assessed through the correlation of 
scale scores and MRA values. Pharmacy refill records were used to 
calculate MRA values, which were equal to the total days of supply 
divided by the number of days during the observation period and 
multiplied by 100 [37]. The primary reason for using the MRA is that the 
measure has been found to be associated with the 8-item MMAS [66, 70]. 
In addition, the MRA is one of the most commonly used medication 
adherence measures in published studies [71-74]. Another reason is due 
to the availability of data. Compared with other pharmacy refill-based 
measures, the MRA requires the least amount of information and 
calculations [37]. Also, compared with other medication adherence 
measures such as electronic pill cap opening monitoring systems, the use 
of MRA is inexpensive and feasible. 
 
Factor analysis and hypothesis testing were conducted to assess the 
construct validity of the scale. Confirmatory factor analysis was 
performed to confirm the scale’s one-factor structure [33]. A root mean 
square error of approximation (RMSEA) equal to or less than 0.05 
indicates a close fit of the model [75]. The following hypotheses were 
tested. A higher scale score is associated with: 
 a higher percentage of INRs within the therapeutic range during the 
past 2 weeks 
 higher adherence to diet recommendations from physicians or 
pharmacists over the past 2 weeks 
 more frequently taking warfarin at the same time of the day over the 
past 2 weeks 
 more frequently taking the dosage of warfarin exactly as prescribed by 
physicians or pharmacists over the past 2 weeks 
 less frequently having difficulty following medication regimens, 




Five response options (i.e. “never”, “rarely”, “sometimes”, “usually” 
and “always”) were provided for questions about adherence to diet  
recommendations, taking warfarin at the same time daily, and perceived 
difficulty following medication regimens. The respondents were divided 
into two groups based on the percentage of INRs in the therapeutic range 
(i.e. “≥ 80%” and “< 80%”) and their adherence to the dosage of warfarin 
exactly as prescribed (i.e. “always” and “not always”). 
 
The sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) of the MMAS for identifying patients with 
poor INR control were assessed using the TTR during the past two weeks 
as the gold standard. For this analysis, patients with an MMAS score of 
less than 8 points were classified as non-adherent; patients with a TTR of 




Descriptive statistics were used to describe the respondents’ 
sociodemographic and disease characteristics. Correlations between scale 
scores and ordinal or continuous variables were examined by Spearman’s 
correlation analysis. The Mann-Whitney U test was used to examine 
associations between scale scores and 1) the percentage of INRs in the 
therapeutic range, and 2) adherence to the dosage of warfarin exactly as 
prescribed. All analyses were performed using Statistical Package for the 
Social Sciences (SPSS) version 19.0. The level of significance was set at 






A total of 184 patients were approached, and 151 patients agreed to 
participate in the survey, giving a response rate of 82.1%. Respondents’ 
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characteristics are shown in Table 2.1. Respondents were equally 
distributed between the two language versions (54.3% English) and the 
two genders (52.3% male). The mean ± standard deviation (SD) age was 
56.0 ± 14.4 years, and most respondents were Chinese (71.5%) and had 
completed secondary education (60.9%). The most common indications 
for warfarin were AF and DVT (23.8% and 47.0%, respectively). Non-
respondents were older than the respondents (p < 0.001) and more likely 
to be Chinese (p = 0.02), and had higher TTR (p = 0.048), while other 
socio-demographics, clinical characteristics and MRA values between the 
respondents and non-respondents were similar (Table 2.1). 
 
Responses to the 8-item MMAS questions 
 
The English and Chinese versions of the 8-item MMAS were combined 
in the analyses, as they were comparable regarding the distributions of 
question responses and scale scores. Separate analyses of the English and 
Chinese versions are summarized in Appendix 2.4. The distribution of 
responses to each question of the 8-item MMAS is shown in Table 2.2. The 
majority of the respondents selected responses that indicated adherence. 
The distribution of scale scores is presented in Figure 2.1. The scale 
scores were skewed, with a median of 7.0 (range = 1.5 to 8.0). The ceiling 
effect was observed, as almost one-third (31.1%) of the respondents had 
a score of 8, indicating the highest adherence to warfarin. The items with 
the most responses indicating poor adherence were forgetting to take 
warfarin (44.4%) and feeling troublesome about sticking to warfarin 




The reliability of the 8-item MMAS was moderate (Cronbach’s alpha = 
0.56). All items contributed to the internal consistency of the scale. A 
small correlation was found between the scale scores and the MRA values 
(rs = 0.17; p = 0.04). Confirmatory factor analysis indicated that the 8-item 
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MMAS was unidimensional (RMSEA = 0.03), and the eight items loaded 
well onto one factor, with factor loadings ranging from 0.20 to 0.81. 
Furthermore, all but one hypothesis were fulfilled. A higher scale score 
was associated with a higher percentage of INRs in the therapeutic range 
(p = 0.01). Small correlations were found between higher scale scores and 
higher adherence to diet recommendations (rs = 0.19; p = 0.02), less 
perceived difficulty following all medication regimens (rs = -0.28; p < 
0.001), and higher likelihood to take warfarin at the same time on each 
day (rs = 0.33; p < 0.001). However, no association was found between the 
scale scores and adherence to the warfarin dosage exactly as prescribed 
(p = 0.09). 
 
The sensitivity of the MMAS indicated that 73.0% of the respondents 
who had poor INR control were identified as non-adherent to warfarin 
therapy, whereas the specificity indicated that 35.6% of the respondents 
who had good INR control were identified as adherent. The PPV indicated 
that 49.5% of the respondents who were non-adherent had poor INR 
control, while the NPV indicated that 60.5% of the respondents who were 





Table 2.1 Patients’ demographic and clinical characteristics (Chapter 2) 
Characteristics 
Respondents 
(n = 151) 
Non-respondents 
(n = 33) 
p value 
 n (%)a  
Language version  0.06 
    English 82 (54.3) 12 (36.4)  
    Chinese 69 (45.7) 21 (63.6)  
Gender  0.30 
    Male 79 (52.3) 14 (42.4)  
    Female 72 (47.7) 19 (57.6)  
Ethnicity  0.02b 
    Chinese 108 (71.5) 30 (90.9)  
    Malay 21 (13.9) 0 (0.0)  
    Indian 14 (9.3) 2 (6.1)  
    Others 8 (5.3) 1 (3.0)  
Educational level  NA 
    No school or primary 58 (38.4) NA  
    Secondary 44 (29.1) NA  
    Post-secondary 48 (31.8) NA  
Indication for warfarin 0.54 
    AF 36 (23.8) 8 (24.2)  
    DVT 71 (47.0) 13 (39.4)  
    Others 40 (26.5) 12 (36.4)  
Percentage of INRs in the therapeutic rangec 0.92 
    < 80 51 (33.8) 12 (36.4)  
    ≥ 80 84 (55.6) 19 (57.6)  
 mean ± SD  
Age (years) 56.0 ± 14.4 67.7 ± 12.9 < 0.001 
TTR (%)c 66.6 ± 39.4 79.2 ± 28.6 0.048 
MRA (%) 93.4 ± 13.8 94.6 ± 9.4 0.66 
a. Percentage may not add up to 100% due to missing values. 
b. Patients were grouped into Chinese and non-Chinese for comparison. 
c. During the two weeks prior to the survey administration.  
AF = atrial fibrillation, DVT = deep vein thrombosis, INR = International 
Normalized Ratio, MRA = medication refill adherence, NA = not available, 
SD = standard deviation, TTR = time in the therapeutic range. 
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Table 2.2 Distribution of responses to items of the 8-item MMAS (n = 151) 





Do you sometimes forget to take your warfarin? 67 (44.4) 84 (55.6) 
Over the past 2 weeks, were there any days when you did not take your warfarin? 15 (9.9) 136 (90.1) 
Have you ever reduced or stopped taking your warfarin without telling your doctor 
or pharmacist because you felt worse when you took it? 
6 (4.0) 145 (96.0) 
When you travel or leave home, do you sometimes forget to bring along your 
warfarin? 
9 (6.0) 142 (94.0) 
Did you take your warfarin yesterday? 149 (98.7) 2 (1.3) 
When you feel like your blood thickness (INR) is within the control range, do you 
sometimes stop taking your warfarin? 
4 (2.6) 147 (97.4) 












How often do you have difficulty remembering to take your warfarin? 100 (66.2) 37 (24.5) 13 (8.6) 1 (0.7) 0 (0.0) 
Use of the © MMAS is protected by US copyright laws. Permission for use is required. A license agreement is available from: Donald E. 
Morisky, ScD, ScM, MSPH, Professor, Department of Community Health Sciences, University of California, Los Angeles, School of Public 
Health, 650 Charles E. Young Drive South, Los Angeles, CA 90095-1772. 
INR = International Normalized Ratio, MMAS = Morisky Medication Adherence Scale.  
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Figure 2.1 Distribution of the 8-item MMAS scores (n = 151) 
 






To the best of our knowledge, this is the first study that validated the 
8-item MMAS in patients taking anticoagulants. The 8-item MMAS was 
originally validated by Morisky et al. to assess patient adherence to 
antihypertensive medications in the US [33]. They found that the scale 
was reliable with good concurrent and predictive validity. Other studies 
validated the 8-item MMAS in patients with diabetes mellitus in Thailand 
[36] and Malaysia [35]. Both studies showed that the scale had moderate 




The 8-item MMAS was found to have varied reliability (Cronbach’s 
alpha = 0.54 to 0.83) in previous studies [33, 35, 36, 65, 67]. The 
moderate reliability in this study might be due to the little variability of 
the scale scores, with more than 60% of the participants having a scale 
score equal to or larger than 7. Moreover, when the reliabilities of the two 
language versions were assessed separately, it was found that the 
Cronbach’s alpha of the English version (i.e., 0.63) was much higher than 
that of the Chinese version (i.e., 0.29), with 59.8% of the participants who 
selected the English version having a scale score equal to or larger than 7, 
compared to 68.1% in those who selected the Chinese version. The 
internal consistency can be improved with greater variability among scale 
scores [76], which would occur in a population with different levels of 
adherence. In other words, when the scale is administered to patients 
with both high and low levels of medication adherence, it will be easier to 
reliably discriminate patients with a high level of medication adherence 
from those with a low level, as compared to the situation in which the 
scale is administered to patients with high medication adherence only 
[76]. In addition, the internal consistency is influenced by the item 
responses of the scale. For example, the “yes” response to the item “Do 
you sometimes forget to take your warfarin?” could include responses 
from both participants who rarely forgot to take warfarin and those who 
often forgot to take warfarin. Therefore, the internal consistency could be 
improved by increasing the item response categories [69, 76]. 
 
As with previous studies [66, 70], the 8-item MMAS scores were 
significantly correlated with the MRA values, showing good criterion-
related validity. In addition, the distributions of both measures were 
skewed to the high end (Figures 2.1 and 2.2), indicating that adherence to 
warfarin in the study population could be actually high. This could be due 
to the fact that the patients at the ACC are well educated about warfarin 
treatment; they may understand that warfarin management is crucial and 
that if they do not adhere to their warfarin therapy, they are more likely 
to have out-of-range INRs and may experience life-threatening conditions. 
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In addition, a large proportion of participants indicated that they were 
using pill boxes to remind them to take warfarin. Moreover, as a 
proportion of these patients were accompanied and looked after by next 
of kin and/or maids, their strong family support may have had enhanced 
those patients’ adherence to their medications. A separate analysis of the 
English and Chinese versions found no association between the MRA and 
MMAS scores. This was not surprising as the sample sizes for the English 
and Chinese versions (i.e., 82 and 69, respectively) were small compared 
with the total sample size (i.e., 151). 
    
 
 
Figure 2.2 Distribution of the MRA values (n = 148) 
 






Consistent with previous studies [48, 77], patients with higher 
medication adherence were found to have a higher percentage of INRs 
within the therapeutic range and higher adherence to diet 
recommendations. It can be postulated that patients with higher 
medication adherence were more likely to be concerned about their 
diseases and were aware of the importance of INR control and the 
recommended diet. As such, these patients were more likely to have INRs 
within the therapeutic range. In this study, patients with higher scale 
scores also perceived less difficulty taking warfarin and co-medications. 
Similar findings were reported in previous studies where complexity of 
medication regimens was found to affect patients’ medication adherence 
[78, 79]. A separate analysis of the English and Chinese versions found 
that some of these associations were not statistically significant, which 
may have been due to the smaller sample sizes. 
 
In this study, the MMAS was found to have a moderate-to-high 
sensitivity and a low specificity that are similar to what have been 
reported in other studies, where blood pressure and hemoglobin A1c 
were used as gold standards in patients with hypertension and diabetes 
mellitus, respectively [33, 35, 36]. In addition, previous studies reported 
that the MMAS had a PPV ranging from 46% to 71% and an NPV ranging 
from 43% to 77% [35, 36]. One explanation for the moderate PPV and 
NPV observed in the present study could be the fact that a number of 
factors other than adherence to warfarin (e.g. genetic variation, dietary 
intake, concomitant medications) can also affect the INR values. Another 
explanation could be social desirability, which may have caused a small 
number of patients to answer the questions in a way that resulted in high 
MMAS scores even if their INR control was less than satisfactory. 
 
The control of INR remains a critical concern in warfarin 
management. Both subtherapeutic and supratherapeutic INRs not only 
increase mortality and reduce patients’ quality of life, but also increase 
the economic burden on the society as well as the patient [16, 19, 20, 80]. 
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Considering the importance of medication adherence to INR control, a 
reliable and valid measure is essential for medication adherence 
assessment in patients taking warfarin in order to get a better 
understanding of patients’ medication-taking behavior and, if needed, 
develop interventions to improve their adherence. As there is no best 
method to assess medication adherence, the selection of measures 
depends on medications and clinical settings [64]. The 8-item MMAS was 
adopted in this study because of its simplicity, feasibility, short 
completion time and low cost [30, 33]. The high response rate with no 
incomplete responses suggested the scale’s acceptability to patients and 
its feasibility in a busy ACC. In addition, the 8-item MMAS assessed 
several factors that may cause patients’ failure to adhere to their 
medications, which could help develop targeted interventions to improve 
adherence. For example, unintentional medication non-adherence (e.g. 
forgetting to take warfarin) and intentional medication non-adherence 
(e.g. stopping taking warfarin when feeling worse) could be reduced by 
the application of a reminder tool (e.g. a pill box) and patient education, 
respectively. Moreover, patients’ non-adherence due to the perceived 
complexity of the medication regimen might be decreased by simplifying 
the regimen plan, if possible [81]. 
 
Modifications may be needed to use the generic 8-item MMAS for 
specific medication regimens or diseases. Additional items may need to be 
added to cover more warfarin-specific adherence-related dimensions and 
to enhance the internal consistency of the scale. For example, Cronbach’s 
alpha increased to 0.61 after two new items were added, which 
investigated if the patient took warfarin at a regular time each day and if 
the patient took the dosage exactly as prescribed. These questions were 
likely useful because both regular timing and appropriate dosage are 
critical to anticoagulation control. The addition of items also reduced the 
ceiling effect observed and further distinguished higher levels of 
adherence from lower levels in those achieving a perfect score on the 
current version of the MMAS. In addition, other language versions, such as 
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Malay and Tamil, need to be developed to meet the demands of non-
English and non-Chinese speaking people in Singapore. Lastly, a 
longitudinal study is needed to assess the responsiveness of the scale.  
 
There are a few limitations to this study. Respondents in this study 
were recruited from an outpatient ACC; therefore, the study sample may 
not be representative of patients with poorer INR control in the inpatient 
setting. In addition, the MMAS scores may have been affected by social 
desirability and recall bias. Another limitation lies in the convenience 
sampling procedure, which may have rendered the study sample liable to 
selection bias. As patients who were non-adherent to prescribed 
medications were less likely to visit their physicians and were more likely 
to have died of non-adherence-induced complications prior to the survey, 
the medication adherence measured may have been inflated. 
 
In conclusion, the 8-item MMAS is easy and practical to use for 
assessing medication adherence in clinical settings. In addition, it helps 
identify patients’ behavioral and attitudinal problems with adherence to 
medication regimens, suggesting when and how healthcare providers can 
intervene or advise. In this study, the 8-item MMAS shows good validity 
and moderate reliability in patients taking warfarin in Singapore. Future 
research is needed to investigate the scale’s psychometric properties in 





Chapter 3 Comparison of Three Medication Adherence 




Non-adherence to warfarin is one of the major contributors to out-of-
range INR values and subsequent complications [17, 27]. Assessment of 
patient adherence to warfarin is essential, as it enables the identification 
of non-adherent patients and elicits a better understanding of those 
patients’ barriers to adherence. This information can assist in improving 
adherence to warfarin therapy, thus enhancing anticoagulation control. In 
addition, assessment of adherence to warfarin therapy can help 
healthcare providers judge if the occurrence of out-of-range INRs is 
caused by poor warfarin adherence or variability in individual responses 
to warfarin doses, and then effective interventions can be implemented to 
achieve good INR control. 
 
There is no best method to evaluate adherence to medication 
regimens. Each method has its own advantages and disadvantages [30, 
63]. The selection of medication adherence measures is important, and 
they need to be specifically chosen for the population and medication in 
question; a measure suitable for one clinical setting may not be applicable 
to another. Therefore, evaluation and comparison of medication 
adherence measures are needed prior to their application in order to 
determine the most suitable measure for the medications and populations 
under investigation. The 8-item MMAS, the VAS and the MRA are 
medication adherence measures that are easy to use and have been 
commonly used to assess patients’ adherence to long-term medications 
[33, 35, 36, 70-74, 82-85]. The aim of this study was to examine the 
associations among three commonly used measures of medication 
adherence: the 8-item MMAS, the VAS and the MRA in patients taking 
warfarin. In addition, the three measures’ associations with patients’ INR 








A cross-sectional survey was conducted from September to December, 
2011, in a convenience sample (i.e. using the most readily available 
patients) of patients taking warfarin in an outpatient ACC of the SGH. The 
target sample size was 155 in order to have a power of 0.8 to detect a 
small correlation (r = 0.25) [68] between warfarin adherence and the 
percentage of INRs within the therapeutic range at the 5% significance 
level, assuming 20% incomplete responses. 
 
The survey questionnaire included the 8-item MMAS, the VAS, socio-
demographics and warfarin-related clinical questions (e.g. indication for 
warfarin) (Appendices 3.1 and 3.2). Two interviewers received training 
on the standardized administration process and data-coding procedure. 
Potentially eligible patients were approached by referral from the ACC 
pharmacists. 
 
Patients were eligible if they were age 21 or older, on warfarin 
therapy for at least 3 months and able to comprehend English or Chinese. 
Proxies (i.e. next of kin) were approached if they looked after the patient 
for his or her warfarin treatment. Respondents who consented to 
participate were interviewed face-to-face and were asked to complete 
either an English or Chinese version of the questionnaire, depending on 
their language preference. The Chinese version of the 8-item MMAS was 
developed and evaluated by a panel of multi-disciplinary and bilingual 
clinical experts based on their clinical expertise and/or experience in 
validation and translation of patient-reported measures. The expert panel 
included one clinical pharmacist with a master’s degree in pharmacy, 
three researchers with a Ph.D. in pharmacy and a Ph.D. candidate in 
pharmacy. The panel ensured equivalence and local adaptation of the two 
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language versions in terms of content, wording, and cognitive levels. The 
two language versions had been pilot-tested in a small group of patients 
on warfarin (n = 8) prior to the survey to ensure the questions’ clarity and 
readability. In addition, patients’ INR records, i.e. the percentage of INRs 
within the therapeutic range and the percentage of TTR during the past 2 
weeks and 3 months, were retrieved from the hospital electronic 
databases. Patients’ INR values were determined by clinical staff using the 
Coaguchek® , an instrument that measures INR values by analyzing blood 
samples; these INR values were then recorded in the hospital databases. 
The study was approved by the Singhealth Institution Review Board.  
 
Medication adherence measures 
 
The 8-item MMAS has been validated in Singapore [86]. The 
underlying theory of the scale was that medication non-adherence could 
be due to patients’ behavioral and attitudinal problems, and, therefore, 
the scale measured several factors that could cause failure to medication 
adherence, including forgetting to take medications, forgetting to bring 
along medications when travelling, not taking medications when feeling 
worse or better, and feeling hassled about sticking to medication 
treatment plans etc. The wording of seven questions was reversed to 
avoid the ‘‘yes-saying’’ bias. Seven items used dichotomous item 
responses (i.e. ‘‘yes’’ and ‘‘no’’), and one item adopted a 5-point Likert-
type item response (i.e. ‘‘never’’, ‘‘rarely’’, ‘‘sometimes’’, ‘‘often’’ and 
‘‘always’’). The scale scores ranged from 0 to 8, with higher scores 
indicating better medication adherence. 
 
The 100-point VAS was a vertical percentile scale anchored by 100 
and 0 at the high and low ends of the scale, respectively. Participants were 
instructed to draw an arrow beside the scale to indicate the extent to 
which they were able to take their warfarin as prescribed in the 2 weeks 
prior to the survey. A point of ‘‘100’’ indicated that the patient was able to 
follow the prescribed warfarin regimen perfectly whereas a point of ‘‘0’’ 
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indicated that the patient was not able to adhere to the prescribed 
warfarin regimen at all. 
 
Warfarin refill records were retrieved for each patient from the 
hospital electronic pharmacy databases in order to calculate the MRA 
value, which was equal to the total days of supply divided by the number 
of evaluated days during the observation period and multiplied by 100 
[37]. The observation period was 3 months to ensure that every patient 




Descriptive statistics were used to describe the respondents’ 
characteristics. Associations among the three measures were examined 
by the Spearman correlation, while the three measures’ associations with 
patients’ INR values were examined by the Spearman correlation and the 
Mann-Whitney U test where appropriate. In the analysis, the respondents 
were divided into two groups based on their percentage of INRs in the 
therapeutic range (i.e., ≥ 80% and < 80%). All analyses were performed 





Among the 202 patients approached, 174 patients or their proxies 
agreed to participate in the survey, giving a response rate of 86.1%. 
Respondents’ characteristics are shown in Table 3.1. Respondents were 
evenly distributed between the two language versions (55.2% English) 
and the two genders (50.0% male), with the mean (SD) age of 58.7 (15.4) 
years. Approximately two-thirds of the participants were Chinese (72.4%) 
and more than half of the participants had completed secondary 
education (55.1%). The major indications for warfarin were AF and DVT 
(28.7% and 43.1%, respectively). Non-respondents were older than the 
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respondents (p = 0.02); other socio-demographics, clinical characteristics, 
and INR and MRA values between the two groups were comparable. 
 
The English and Chinese versions of the questionnaire were 
combined in the analyses, as they were comparable in distributions of 
responses and scale scores. The mean (SD) of the MMAS scores, the VAS 
scores and the MRA values were 7.0 (1.1), 91.9 (10.8) and 93.6% (13.7%), 
respectively. The distributions of the three measures were trended 
towards the high end, indicating high adherence to warfarin.  
Approximately one-third (34.5%) of the respondents had an MMAS score 
of 8, while 46.6% of the respondents had a VAS score of 100 and 63.2% of 
the respondents had an MRA value of 100% (Figure 3.1). With a VAS 
score of 80 serving as a cut-off point, 89.1% of the respondents were 
considered to have good adherence to warfarin; with an 80% warfarin 
refill rate serving as a cut-off point, 85.1% of the respondents were 
considered adherent. 
 
Correlations among the three medication adherence measures are 
shown in Table 3.2. Small correlations were found between the MMAS 
scores and both the VAS scores and the MRA values (rs = 0.23 and 0.18; p 
= 0.002 and 0.02, respectively) whereas no association was found 
between the VAS scores and the MRA values (rs = 0.08; p = 0.32). 
Associations between the three adherence measures and four INR 
measures are shown in Table 3.3. Small correlations were found between 
the MRA values and the percentage of TTR in the past 3 months and past 
2 weeks (rs = 0.21 and 0.16; p = 0.01 and 0.045, respectively). The MRA 
values were also associated with the percentage of INRs within the 
therapeutic range in the past 2 weeks (p = 0.03). The MMAS scores were 
only associated with the percentage of INRs within the therapeutic range 
in the past 2 weeks (p = 0.02). The VAS scores were not associated with 




Table 3.1 Patients’ demographic and clinical characteristics (Chapter 3) 
Characteristics 
Respondents 
(n = 174) 
Non-respondents 
(n = 28) 
p value 
 n (%)a  
Language version  0.06 
    English 96 (55.2) 10 (35.7)  
    Chinese 78 (44.8) 18 (64.3)  
Interviewee’s role  0.54 
    Patient 151 (86.8) 26 (92.9)  
    Next of kin 23 (13.2) 2 (7.1)  
Gender  0.48 
    Male 87 (50.0) 12 (42.9)  
    Female 87 (50.0) 16 (57.1)  
Ethnicity  0.06b 
    Chinese 126 (72.4) 25 (89.3)  
    Malay 25 (14.4) 1 (3.6)  
    Indian 14 (8.0) 2 (7.1)  
    Others 9 (5.2) 0 (0.0)  
Educational level  NA 
    No school or primary 76 (43.7) NA  
    Secondary 46 (26.4) NA  
    Post-secondary 50 (28.7) NA  
Indication for warfarin 0.38 
    AF 50 (28.7) 5 (17.9)  
    DVT 75 (43.1) 13 (46.4)  
    Others 45 (25.8) 10 (35.7)  
INRs in the therapeutic range in the past 3 months (%) 0.85 
    < 80  94 (54.0) 15 (53.6)  
    ≥ 80  68 (39.1) 10 (35.7)  
INRs in the therapeutic range in the past 2 weeks (%) 0.59 
    < 80 63 (36.2) 9 (32.1)  









(n = 174) 
Non-respondents 
(n = 28) 
p value 
 mean ± SD  
Age (years) 58.7 ± 15.4 66.2 ± 12.9 0.02 
TTR in the past 3 months (%) 64.5 ± 33.8 74.3 ± 28.4 0.26 
TTR in the past 2 weeks (%) 65.3 ± 39.4 79.7 ± 30.0 0.13 
MRA (%) 93.6 ± 13.7 0.94 ± 0.10 0.69 
a. Percentage may not add up to 100% due to missing values.  
b. Patients were grouped into Chinese and non-Chinese for comparison. 
AF = atrial fibrillation, DVT = deep vein thrombosis, INR = International 
Normalized Ratio, MRA = medication refill adherence, NA = not available, 




Figure 3.1 Distributions of responses to the medication adherence measures 
 






Table 3.2 Correlations among the 8-item MMAS, VAS and MRA  
 
rs p value 
MMAS 
VAS 0.23 0.002 
MRA 0.18 0.02 
 VAS 
MRA 0.08 0.32 
MMAS = Morisky Medication Adherence Scale, MRA = medication refill 




Table 3.3 Associations between medication adherence and INR measures 
 Percentage of TTR  
Past 3 months Past 2 weeks 
rs p value rs p value 
MMAS 0.07 0.38 0.10 0.23 
VAS -0.02 0.79 0.05 0.57 
MRA  0.21 0.01 0.16 0.045 
 
Percentage of INR in the therapeutic rangea 
Past 3 months Past 2 weeks 
rs p value rs p value 
MMAS NA 0.20 NA 0.02 
VAS NA 0.99 NA 0.31 
MRA  NA 0.35 NA 0.03 
a. Mann-Whitney U test was used. 
INR = International Normalized Ratio, MMAS = Morisky Medication Adherence 
Scale, MRA = medication refill adherence, NA = not applicable, TTR = time in the 







The primary objective of the study was to compare the 8-item MMAS, 
the VAS and the MRA in patients taking warfarin. To the best of our 
knowledge, this is one of the few studies that compared pharmacy refill 
data-based and patient-reported medication adherence measures, and is 
the first study that compared the three adherence measures in a multi-
ethnic Asian population. 
 
Previous studies have employed various adherence measures and 
found that patients generally have good adherence to warfarin therapy. 
For example, Orensky and Holdford [48] found that 80% patients were 
deemed adherent to warfarin, using a cut-off level of an 80% warfarin 
refill rate. Platt et al. [87] reported that patients were adherent to 
warfarin in 78.7% of patient-days observed in a study using an electronic 
pill cap opening monitoring system. As in the previous studies, the 
distributions of the MMAS scores, the VAS scores and the MRA values in 
this study were skewed to the high end, indicating that most patients 
were adherent to warfarin therapy. The high warfarin adherence could be 
due to the use of a pill box, as mentioned by the majority of the 
respondents. Another explanation could be the critical nature of warfarin, 
which frequently subjects patients to severe complications and even 
death and, therefore, discourages patients from being non-adherent [7, 16, 
19, 20]. In addition, strong family support may have enhanced patients’ 
adherence to warfarin, as a few patients were looked after by their next of 
kin. 
 
In this study, the 8-item MMAS scores were found to be associated 
with both the VAS scores and the MRA values. Similar findings have been 
reported by other studies. Krousel-Wood et al. [70] found that the 8-item 
MMAS was associated with three pharmacy refill adherence measures in 
elderly patients with hypertension. Another study that assessed patients’ 
adherence to diabetes medications found that patients with higher 8-item 
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MMAS scores were more likely to have higher VAS scores [36]. 
Nevertheless, the associations between MMAS and the other two 
measures found in this study were small, and no significant association 
was found between the VAS scores and the MRA values. This could be due 
to the different observation periods of the three measures. The MRA 
assessed patients’ adherence over the past 3 months, whereas the VAS 
evaluated patients’ adherence over the past 2 weeks and the MMAS, 
which was composed of questions with specified (from yesterday to the 
past 2 weeks) and non-specified observation periods, assessed the most 
recent warfarin-taking behavior. Another explanation could be that the 
three measures assessed different aspects of medication adherence. The 
MRA assessed the patient’s behavior regarding warfarin refills, assuming 
that the patient took warfarin every day as prescribed if the refill was 
collected on time. In the two self-reported measures, the MMAS evaluated 
the patient’s behavioral and attitudinal problems related to medication 
adherence, whereas the VAS assessed the patient’s perceived adherence 
and allowed for the patient’s own interpretation and evaluation of his or 
her warfarin-taking behavior, which may have caused additional 
variability in the scale scores. Moreover, consistent with the findings of a 
previous study [88], a few elderly respondents with low literacy had 
difficulty comprehending the VAS, which required abstract thinking, and 
the accuracy of their responses and thus their VAS scores may have been 
compromised.  
 
Despite the a priori expectation that patients with better medication 
adherence would be more likely to have better INR control, the 
associations between the MMAS scores and the INR control measures 
were not conclusive in this study. One explanation could be that the 
MMAS is a generic measure of medication adherence and does not cover 
all dimensions of warfarin-specific adherence. For example, regular 
timing of daily warfarin doses was found to be associated with the 
percentage of TTR [89]. Moreover, the MMAS may include questions that 
are not sensitive to different levels of warfarin adherence. For example, 
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although a number of the respondents indicated that they felt it was 
troublesome to stick to their warfarin regimen plans, they remained 
adherent in order to reduce the risk of complications. In addition, the 
dichotomous item responses of the MMAS may make the scale difficult to 
differentiate among patients with higher levels of adherence and, as a 
result, diminish potential associations between the scale scores and the 
INR values. Moreover, a number of factors (e.g. diet and lifestyle) other 
than medication adherence can also affect patients’ INR control. 
 
Among the various medication adherence measures, the 8-item 
MMAS, the VAS and the MRA have a number of advantages and have been 
used in patients with a variety of diseases. The 8-item MMAS has been 
shown to have moderate reliability and good validity in patients taking 
warfarin in Singapore, and is simple to understand and easy to administer 
[86]. It has been used to assess medication adherence in patients with 
diseases such as hypertension [33, 70], diabetes mellitus [35, 36] and 
epilepsy [82]. The VAS is another self-report measure that features its 
brevity, low response burden and easy incorporation into a medical visit, 
and it has been used in patients with diseases such as diabetes mellitus 
[85], asthma [84] and human immunodeficiency virus [83]. The MRA, 
which has been commonly used in patients with diseases such as diabetes 
mellitus [71], human immunodeficiency virus [72], cystic fibrosis [74] and 
inflammatory bowel disease [73], is an objective method based on refill 
data and, therefore, it is not susceptible to social desirability and recall 
bias. In addition, it requires the fewest calculations and the least amount 
of data compared to other measures that use pharmacy administrative 
data [37]. In this study, it was found that the MRA had a significant 
correlation with most of the INR measures, and, therefore, may be 
incorporated into clinical practice to help identify patients with poor INR 
control. Moreover, MRA can assess medication adherence in patients who 
refuse to report their medication adherence or often miss their clinic 
visits, who are likely to be in the greatest need of targeted interventions 
to improve their medication adherence. Future research is needed to 
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compare the MRA or TTR with other medication adherence measures 
such as the electronic monitoring system that has been used as a gold 
standard in several studies [90, 91]. However, the electronic monitoring 
system is expensive and, therefore, its application may be limited.  
Moreover, a longitudinal study is needed to evaluate the changes in MRA 
over time to get a better understanding of patients’ long-term medication 
adherence. 
 
There are a few limitations to this study. Patients were recruited from 
an outpatient ACC, so the findings may not be generalizable to inpatients 
or other ambulatory patients not cared for by ACCs, such as those 
managed by their primary care providers, who may have poorer INR 
control. Another limitation is that the actual adherence to warfarin may 
have been inflated, as the convenience sampling procedure of the survey 
may have rendered the study sample liable to selection bias. Patients who 
were non-adherent to warfarin were more likely to have missed their 
clinic appointments and to have subjected themselves to non-adherence-
induced fatal complications prior to the survey. In addition, the actual 
medication adherence may have been overestimated because of the social 
desirability and recall bias of patient-reported measures and the 
assumption of the MRA that patients took warfarin as prescribed. 
 
In conclusion, measure selection is essential to assessing patients’ 
adherence to medication regimens. In this study, most of the patients on 
warfarin were adherent as indicated by three adherence measures. In 
addition, the pharmacy refill data-based MRA was found to be associated 
with INR control and self-reported MMAS but not VAS. The findings 
provided insight into the correlations and differences among three 
medication adherence measures and their associations with INR control, 
which may assist healthcare providers to select the most suitable 
measure for the assessment of warfarin adherence. Future research is 




Chapter 4 Knowledge, Satisfaction, and Concerns regarding 
Warfarin Therapy and Their Associations with Warfarin 
Adherence and Anticoagulation Control in Patients Taking 




It is important to adhere to warfarin treatment as prescribed and 
keep INRs within the therapeutic range. A number of other factors may 
affect INR control in patients taking warfarin. Some factors are inherent, 
such as genetic variants that can lead to variability in inter-individual 
warfarin doses and difficulty achieving better INR control [23]. However, 
other factors that facilitate good INR control are acquired and can be 
controlled via patients’ behavior. For example, studies have shown that 
patients with better knowledge and higher medication adherence to 
warfarin therapy are more likely to have good INR control [43, 92]. As 
such, it is important to assess and identify the deficits in patients’ 
knowledge as well as their satisfaction with and concerns of warfarin 
therapy, all of which may lead to poor warfarin adherence and INR 
control. With a better understanding of the gaps and needs, targeted 
interventions can be developed and incorporated into patient education 
and clinical practice.  
 
The aims of this study were two-fold: 1) to identify deficits in patients’ 
knowledge as well as their satisfaction with and concerns of warfarin 
therapy, and 2) to assess these results’ associations with warfarin 








A cross-sectional survey was conducted in a convenience sample of 
patients taking warfarin in an ACC of the SGH from November, 2012, to 
April, 2013. The target sample size was 180 in order to have a power of 
0.8 to detect a small correlation (r = 0.25) [68] between patients’ 
knowledge of warfarin therapy and INR control at the 5% significance 
level, assuming 30% incomplete responses. To be eligible, participants 
had to be age 21 or older, taking warfarin and able to comprehend English 
or Chinese. Participants who consented to participate were interviewed 
face-to-face in English or Chinese, depending on their language 
preference. Prior to survey administration, two interviewers were trained 
in order to standardize the administration process. The study was 
approved by the Singhealth Institution Review Board. 
 
Based on the findings in Chapter 3, i.e., that the MRA was associated 
with most INR measures and might be a more suitable measure for 
adherence to warfarin than the MMAS and VAS, the MRA was used to 
assess patients’ adherence to warfarin. Patients’ warfarin refill records for 
the past three months prior to survey administration were retrieved from 
the hospital electronic databases in order to calculate the warfarin refill 
adherence, which was equal to the total days of supply divided by the 
number of evaluated days during the observation period, multiplied by 
100 [37]. In addition, patients’ TTR in the past 2 weeks were also 
retrieved from the same databases. Patients with a TTR of 90% or higher 




The survey questionnaire was developed based on literature review 
[27, 38-51, 93-100], patient educational materials provided by the ACC 
and expert opinions (Appendices 4.1 and 4.2). The questionnaire was 
composed of four parts, including patients’ socio-demographic and 
warfarin-related clinical characteristics (e.g., duration of taking warfarin), 
knowledge of warfarin treatment, satisfaction with services and warfarin 
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treatment provided by the ACC, and concerns of warfarin therapy. The 
two language versions of the questionnaire were evaluated by a panel of 
multi-disciplinary and bilingual clinical experts (i.e., a researcher with a 
Ph.D. degree in pharmacy, two physicians with a master’s degree in 
medicine, a clinical pharmacist with a master’s degree in pharmacy and a 
Ph.D. candidate in pharmacy) to ensure local adaptation and equivalence 
in terms of content, wording and cognitive levels. Both language versions 
were pilot-tested in a group of patients (n = 16) prior to the survey to 
ensure the questions’ clarity and readability.  
 
The knowledge questions consisted of four domains, including 
warfarin administration (e.g., color of warfarin tablets), warfarin-drug 
interactions (e.g., interaction between warfarin and aspirin), warfarin-
diet interactions (e.g., interaction between warfarin and soybean 
products) and adverse effects (e.g., symptoms of warfarin-induced 
hemorrhage). Each domain consisted of two to four questions, giving a 
total of eleven questions. Each question had five options, only one of 
which was correct. A score of “1” was assigned to each correctly chosen 
option, giving a total knowledge score that ranged from 0 to 11, with a 
higher score indicating better knowledge.  
 
The satisfaction scale included seven positive statements about the 
services and warfarin treatment provided by the ACC with Likert-type 
responses, and each response was assigned a score based on level of 
satisfaction (i.e., “strongly agree” = 4, “agree” = 3, “neutral” = 2, “disagree” 
= 1 and “strongly disagree” = 0). Therefore, the total scores of the seven 
statements ranged from 0 to 28, with a higher score indicating a higher 
level of satisfaction.  
 
The questionnaire also assessed patient-perceived concerns of 
warfarin therapy. Ten potential concerns were listed, including warfarin-
drug interactions, forgetting to take warfarin, side effects of warfarin, 
frequency of hospital visits, warfarin-diet interactions, restrictions on 
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usual activities, impact on work, not believing that warfarin is helpful, 
difficulty following warfarin instructions and other concerns. Each 
concern was given a score of “1”. Patients were asked to tick all concerns 
they experienced. The total score ranged from 0 to 10, with a higher score 




Descriptive statistics were used to describe patients’ characteristics 
along with their knowledge, satisfaction and concern scores. Pearson’s 
Chi-Square test and independent sample t-test were used where 
appropriate to compare socio-demographic and clinical characteristics 
between respondents and non-respondents. Independent sample t-test 
and Mann-Whitney U test were used where appropriate to compare the 
difference in knowledge, satisfaction and concern scores between 
patients with and those without good INR control. Correlation between 
knowledge and satisfaction scores was examined using Pearson’s 
correlation analysis. Spearman’s correlation analysis was used to examine 
1) the correlations of concern scores with knowledge and satisfaction 
scores, and 2) the correlations of warfarin refill adherence with 
knowledge, satisfaction and concern scores. All analyses were performed 
using SPSS version 19.0. The level of significance was set at probability 






Among the 258 patients approached, 183 agreed to participate in the 
survey, giving a response rate of 70.9%. Patients’ characteristics are 
shown in Table 4.1. Respondents were evenly distributed between the 
two genders (49.2% male) and the two language versions (54.6% 
English), had a mean ± SD age of 56.1 ± 13.0 years and mean ± SD 
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warfarin refill adherence of 92.0 ± 16.8% and had been taking warfarin 
for a mean ± SD duration of 7.4 ± 7.5 years. A majority of respondents 
were Chinese (69.9%), married (70.5%), had DVT (51.4%) and TTR of 
less than 90% (56.8%), and had completed secondary or post-secondary 
education (66.2%). Non-respondents were older (p = 0.002) and more 




The mean ± SD knowledge score was 6.6 ± 2.3 (Figure 4.1). More 
elderly patients (r = -0.47, p < 0.001) and those with lower education (p < 
0.001) were more likely to have poor knowledge regarding warfarin 
treatment. A number of patients (16.9%) gave wrong answers to both 
questions in the domain of warfarin-diet interactions, and others 
incorrectly answered questions about warfarin-drug interactions 
(10.9%), warfarin adverse effects (10.4%) and warfarin administration 
(3.8%) (Table 4.2). The major knowledge deficits were identified as 
follows: impact of warfarin on intramuscular injections (67.2% answered 
incorrectly), medicines that interacted with warfarin (54.1%), food that 
interacted with warfarin (53.0%), associations between warfarin dosage, 
INR control and subsequent clinical complication (49.7%) and frequency 
of monitoring signs of bleeding (45.4%). On the contrary, patients were 
more likely to have a good knowledge regarding the need to consult 
doctors when starting a new medicine (82.0%), the color and number of 
daily warfarin tablets as prescribed (78.7%), symptoms of bleeding 
(73.2%), the importance of keeping a consistent diet (68.9%), the actions 







Table 4.1 Patients’ demographic and clinical characteristics (Chapter 4) 
Characteristics 
Respondents 
(n = 183) 
Non-respondents 
(n = 75) 
p value 
 n (%)a  
Gender  0.68 
    Male 90 (49.2) 39 (52.0)  
    Female 93 (50.8) 36 (48.0)  
Ethnicity  0.50 
    Chinese 128 (69.9) 58 (77.3)  
    Malay 32 (17.5) 9 (12.0)  
    Indian 13 (7.1) 6 (8.0)  
    Others 10 (5.5) 2 (2.7)  
Language  0.02 
    English 100 (54.6) 29 (38.7)  
    Chinese 83 (45.4) 46 (61.3)  
Educational level  NA 
No school or primary 61 (33.3) NA  
    Secondary 66 (36.1) NA  
    Post-secondary 55 (30.1) NA  
Marital status NA 
    Married 129 (70.5) NA  
    Not married 54 (29.5) NA  
Indication for warfarin 0.14 
    AF 22 (12.0) 16 (21.3)  
    DVT 94 (51.4) 32 (42.7)  
    Others 64 (35.0) 26 (34.7)  
TTR in the past 2 weeks (%) 0.76 
    < 90 104 (56.8) 45 (60.0)  
    ≥ 90 73 (39.9) 29 (38.7)  
 mean ± SD  
Age (years) 56.1 ± 13.0 61.7 ± 12.8 0.002 
Years for taking warfarin  7.4 ± 7.5 NA NA 
a. Percentage may not add up to 100% due to missing values.  
AF = atrial fibrillation, DVT = deep vein thrombosis, NA = not available, SD 
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The satisfaction scale had a mean ± SD score of 21.2 ± 3.6. Responses 
to each statement are listed in Table 4.3.  A number of patients (43.2%) 
were neutral about or unsatisfied with the waiting time to see an ACC 
pharmacist as well as the frequency of ACC appointments (20.2%). 
 
The concern scores had a median of 1 and were skewed to the high 
end. Patients who were new on warfarin were more likely to have more 
concerns (rs = -0.21, p = 0.004). Approximately one-third (31.7%) of the 
respondents indicated no concerns. The most commonly reported 
concerns were worries about warfarin-drug interactions (36.1%), 
followed by forgetting to take warfarin (26.2%), worries about side 
effects of warfarin (25.7%), the high frequency of hospital visits (24.0%) 
and worries about warfarin-diet interactions (22.4%). 
 
It was found that higher satisfaction scores were associated with both 
higher knowledge scores (r = 0.24, p = 0.001) and lower concern scores 
(rs = -0.23, p = 0.002). Moreover, patients with better knowledge and 
higher satisfaction were more likely to have high warfarin refill 
adherence (rs = 0.21 and 0.16; p = 0.01 and 0.046, respectively). Finally, 
patients with better knowledge, higher satisfaction, fewer concerns and 
better warfarin adherence were more likely to have good  INR control (p 
= 0.003, 0.009, 0.02 and 0.048, respectively). Knowledge, satisfaction and 
concern scores as well as warfarin adherence in patients with good and 










Agree Neutral Disagree 
Strongly 
disagree 








2 (1.1) 1 (0.5) 








6 (3.3) 1 (0.5) 







1 (0.5) 0 (0.0) 








5 (2.7) 0 (0.0) 
Since you began your treatment at the ACC, your blood thickness (INR results) has 







5 (2.7) 0 (0.0) 








9 (4.9) 0 (0.0) 







21 (11.5) 5 (2.7) 
ACC = anticoagulation clinic, INR = International Normalized Ratio, SGH = Singapore General Hospital. 
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Table 4.4 Knowledge, satisfaction and concern scores as well as warfarin 
refill adherence in patients with good and poor INR control 
Variable 




Knowledge score 7.2 ± 2.0 6.2 ± 2.4 0.003 
Satisfaction score 22.1 ± 2.9 20.7 ± 3.8 0.009 
Concern score 1.3 ± 1.4 1.8 ± 1.6 0.02 
MRA (%) 94.0 ± 13.1 90.1 ± 19.3 0.048 







In this study, on average, patients had a moderate level of warfarin 
knowledge. This finding was consistent with a few previous studies that 
found poor to moderate levels of warfarin knowledge in patients taking 
warfarin [43, 101, 102]. However, a closer look at patients’ responses 
revealed that there were some consistent knowledge deficits in most 
respondents. In particular, similar to the findings of previous studies [42, 
103], patients had inadequate knowledge of warfarin-diet interactions 
and warfarin-drug interactions. Studies have shown that changes in 
dietary intake of vitamin K can impact the effect of warfarin and lead to 
unstable INR control [104, 105]. In addition, it is known that patients 
taking warfarin are susceptible to a number of drug interactions, which 
may lead to severe bleeding [106]. Therefore, the findings of this study 
demonstrated that future patient educational programs should focus on 
warfarin-diet and warfarin-drug interactions. Continuous educational 
programs are suggested, as patients may have forgotten what they have 




Consistent with previous studies [43, 107], it was found that more 
elderly patients and patients with poorer education were more likely to 
have poor knowledge of warfarin treatment. This could be due to the fact 
that these patients had more difficulty comprehending educational 
materials (e.g., the educational booklet provided by the ACC) and 
communicating with healthcare providers. In a busy ACC, patients are 
often assumed to be able to comprehend written educational materials 
and oral communication about their warfarin treatment, and the problem 
of inadequate health literacy in older and poorly educated patients may 
be overlooked. The lack of knowledge about warfarin treatment in elderly 
patients can severely affect patients’ INR control because they often take 
several medications simultaneously for multiple chronic conditions, 
which subjects them to a high risk of warfarin-drug interactions [106]. 
Therefore, education in these patients may require special consideration. 
Innovative and patient-targeted educational programs (e.g., video-
assisted programs) and improvement in pharmacist-patient 
communication are needed [108, 109]. 
 
In this study, patients had a moderate level of satisfaction with 
services and warfarin treatment provided by the ACC. The largest 
complaint was about the long waiting time to visit an ACC pharmacist, 
which could be due to the large number of daily appointments and limited 
healthcare resources in the busy ACC. The number of pharmacists needs 
to be increased to reduce patients’ waiting time, which may also increase 
the time for pharmacist-patient communication and improve the current 
services at the clinic.  
 
A number of respondents reported worries about warfarin-drug 
interactions, the side effects of warfarin and warfarin-diet interactions. 
These concerns could be overcome by improving relevant knowledge of 
warfarin treatment via patient education, particularly for those who have 
newly started warfarin treatment. Moreover, interventions such as pill 
boxes can be used to help patients who forget to take warfarin to improve 
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their adherence to warfarin therapy. For patients who found that it was 
difficult to take warfarin due to frequent hospital visits, home INR testing 
may be implemented based on structured patient training [94]. A few 
studies have supported self-management of INR control because it 
incorporates more frequent INR tests, higher levels of medical safety and 
less frequent hospital visits [110, 111].  
 
One approach to keeping INRs within the therapeutic range is to 
control the risk factors of out-of-range INRs, which can be either genetic 
or environmental. Genetic factors (e.g., variants of Cytochrome P450 2C9 
and vitamin K epoxide reductase complex subunit 1) can lead to 
variability in inter-individual responses to warfarin doses and thus 
require individualized dosing strategies [112, 113]. These factors are 
inherent and cannot be controlled by patients’ behavior. In contrast, 
environmental factors (e.g., dietary intake of vitamin K) are acquired and 
can be controlled by patients in order to improve their INR control. 
Consistent with previous findings [43], it was found that patients with 
better knowledge, higher satisfaction and fewer concerns regarding 
warfarin therapy were more likely to have good INR control, indicating 
the significant effects of these factors on INR control and the importance 
of controlling them. In addition, consistent with previous studies [48, 92], 
it was found that poor adherence to warfarin treatment could adversely 
affect patients’ INR control. In this study, it was found that patients with 
better knowledge and higher satisfaction regarding warfarin treatment 
were more likely to adhere to warfarin, further demonstrating the 
importance of improving patients’ knowledge and satisfaction.  
 
There are several limitations to this study. First, respondents in this 
study were recruited from an outpatient ACC; therefore, the findings may 
not be generalizable to patients with poorer INR control in the inpatient 
setting. Second, selection bias may have existed due to the convenience 
sampling procedure. Patients with poorer knowledge and lower 
satisfaction may have had poorer medication adherence and may have 
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been less likely to visit healthcare providers or more likely to have passed 
away as a consequence of non-adherence. Third, the MRA used in this 
study assumed that patients took warfarin every day as prescribed if the 
refill was collected on time. Their actual adherence to warfarin may have 
been inflated. 
 
In conclusion, the findings of this study highlighted the deficits in 
patients’ knowledge and satisfaction regarding warfarin therapy and 
concerns of taking warfarin and identified the areas for improvement in 
patient education. In addition, this study demonstrated the associations of 
patients’ knowledge, satisfaction and concerns regarding warfarin 
treatment with warfarin adherence and INR control, indicating that the 
negative impact of these deficits on the effect of warfarin therapy could be 
important and severe. Therefore, patient-targeted and structured 
educational programs as well as efficient pharmacist-patient 
communication are needed to make warfarin treatment more successful.  
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Stroke remains the second leading cause of global mortality and 
accounts for approximately 10% of all-cause mortality, leading to more 
than 6 million deaths at present and a projected 8 million deaths per year 
in 2030 [1, 114]. Fifty percent of stroke survivors have life-long moderate 
and severe post-stroke disabilities that greatly impair their health-related 
quality of life (HRQoL) [114]. Therefore, stroke prophylaxis is crucial, 
especially in patients with AF who are at a four- to five-fold increased risk 
of stroke [5].  
 
Oral anticoagulation therapies have been commonly used to prevent 
strokes, and warfarin has been the cornerstone for more than half a 
century [7]. Recently, two novel oral anticoagulants, i.e., dabigatran and 
rivaroxaban, have been approved to prevent strokes in patients with AF 
in several countries. Studies have shown that patients on anticoagulation 
therapies may experience different levels of impaired health states such 
as recurrent stroke and bleeding [53, 55]. Some of these health states are 
associated with long-term physical disabilities that greatly impair 
patients’ HRQoL. Therefore, in addition to clinical outcomes, it is also 
important to assess patients’ preferences (i.e., utilities) for various health 
states related to anticoagulation therapies, which can provide insight into 
patient-perceived impact of stroke prophylaxis on their HRQoL. 
 
Previous studies have assessed patients’ utilities for anticoagulant-
related health states [115-119]. However, most of them focused on major 
and minor ischemic strokes [115, 116, 118, 119]. Moreover, none was 
conducted in an Asian population. This study is the first one that elicits 
patients’ utilities for not only major and minor ischemic strokes, but also 




Commonly used direct methods to assess patients’ utilities include 
rating scale, time trade-off (TTO) and standard gamble (SG) [120]. The 
rating scale method, e.g., the VAS, is easy to understand and administer. It 
is often used together with and prior to other utility measures as a 
complement to familiarize patients with health states under evaluation. 
The TTO elicits patients’ utilities by assessing the amount of time in a 
perfect health state that is equivalent to a period of time in a poor health 
state. This method is often used to assist decision-making that involves 
trade-offs between longevity and quality of life. The SG, based on the 
axioms of expected utility theory (EUT) [121], elicits patients’ utilities by 
assessing how much risk they are willing to take to avoid staying in a poor 
heath state. Healthcare decisions (e.g., choices of stroke prophylactic 
therapies) often involve patients’ attitudes towards risks and 
uncertainties of therapeutic failure and adverse effects, which can be 
captured by the SG; this method has been advocated by some researchers 
[116, 117].  
 
This study aimed to use the VAS and SG to elicit patients’ utilities for 
health states related to stroke prophylaxis using three oral anticoagulants 
(i.e., warfarin, dabigatran, and rivaroxaban) in a multi-ethnic Asian 






A cross-sectional survey was administered to a convenience sample 
of patients taking warfarin in an ACC of the SGH from August to 
November in 2012. Prior to survey administration, two interviewers were 
trained to standardize the administration process and data collection 
procedure. Potentially eligible patients were identified by referral from 
the ACC pharmacists. To be eligible, participants had to be age 21 or older, 
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on warfarin and able to comprehend English or Chinese. Respondents 
who consented to participate were interviewed face-to-face in either 
English or Chinese depending on their language preference. Patients who 
had cognitive problems (e.g., unable to communicate) were excluded. The 
target sample size was 100 in order to have a power of 0.8 to detect a 
small difference (i.e., 0.1 with an SD of 0.2) between utilities for major and 
minor ischemic strokes at the 5% significance level (two-sided test), 
assuming 60% incomplete responses. The sample size was consistent 
with those in previous published studies that used the SG to elicit utilities 
for hypothetical health states [122]. The study was approved by the 




A questionnaire was developed specifically for this study to collect 
information about patients’ socio-demographics and clinical 
characteristics (e.g., duration of taking warfarin) (Appendices 5.1 and 
5.2).   In addition, patients’ INR values in the past 3 months prior to the 
survey administration were retrieved from hospital databases.  
 
Health state selection and descriptions 
 
Seven long-term and four short-term health states were selected 
based on their relevance to the oral anticoagulation therapies in patients 
with AF. The long-term health states included “well on warfarin”, “well on 
dabigatran”, “well on rivaroxaban”, major ischemic stroke, minor ischemic 
stroke, intracranial hemorrhage (ICH) and current health state. It was 
assumed that patients would stay in the long-term health states for the 
rest of their life. The short-term health states included transient ischemic 
attack (TIA), major extracranial hemorrhage (ECH), minor ECH and MI. 
Patients would return to their good health after staying in a short-term 
health state for a pre-determined period. Two additional health states 




Descriptions of health states were developed based on preference 
assessment guidelines [123, 124], medical textbooks [125-128], 
published literature [53, 55, 115-117, 119, 129-145], and expert opinions, 
i.e., two researchers with Ph.D. degrees in pharmacy, two clinical 
researchers with Pharm.D. degrees, two physicians with master’s degrees 
in medicine, a clinical pharmacist with a master’s degree in pharmacy and 
a Ph.D. candidate in pharmacy (Appendices 5.3 and 5.4). The descriptions 
for each health state consisted of one to six bullet points that described 
the health state’s important attributes, such as patients’ physical mobility 
in the state. The descriptions  were presented on cards in a neutral 
manner to reduce framing bias [146]. Each card was numerically labeled 




Utilities for health states were elicited based on the procedures 
recommended by published guidelines [120, 123, 146, 149]. The VAS 
followed by the SG was used to elicit utility values. The VAS is a feeling 
thermometer (i.e., a vertical percentile scale) anchored by 100 (most 
desirable health state) and 0 (least desirable health state) at the high and 
low ends of the scale, respectively [120, 123, 146], with a higher value 
indicating higher desirability for a health state. Participants were 
instructed to rank all the health state cards from the most to least 
desirable, place them on the VAS based on their relative preferences (i.e., 
how good or bad a health state was compared to other health states), and 
then write a score for each card. Perfect health and immediate death were 
ranked together with the other long-term health states. If the patient 
considered all health states to be better than death, raw scores for health 
states were converted to a 0 (immediate death) to 1 (perfect health) 
utility scale by dividing the raw scores by 100 [120, 146]. In this way, 
utility for death was equal to 0, and those for other health states were 
between 0 and 1. If the patient considered a health state to be worse than 
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death, a linear transformation was used to convert the raw scores to the 0 
to 1 utility scale, using the formula  (x – d) / (100 – d), where x and d 
denoted the raw score of the health state being measured and that of 
death, respectively [120, 146, 150]. In this way, utilities for health states 
better than death were between 0 and 1, and those for health states 
worse than death were between -1 (the worst possible health state) to 0 
(death). 
 
In the SG method, visual aids (i.e., chance boards) were used to elicit 
patients’ utilities (Appendices 5.5 and 5.6). If the patient considered all 
long-term health states to be better than death, two choices were given: 
1) staying in the health state under evaluation for the rest of his life, and 
2) a gamble in which there was a probability (“p”) of living in perfect 
health and a probability (“1-p”) of immediate death [120, 123, 146, 149]. 
Probabilities of perfect health and immediate death were presented in a 
“ping-pong” approach that began with a 100% chance of perfect health 
and a 0% chance of immediate death, followed by a 5% chance of perfect 
health and a 95% chance of immediate death, and so on. The probabilities 
were shifted back and forth until 1) the participant felt indifferent to the 
two choices (the value of “p” derived at that point was the respondent’s 
utility value for that particular health state), or 2) the participant kept his 
previous choice even if the probabilities were shifted (the value of “p” 
derived at that point plus half increment, i.e., 2.5%, was the respondent’s 
utility value for that particular health state) [123].  
 
If the respondent indicated that the health state being measured was 
worse than death, the SG method was modified [123, 146, 149], and the 
respondent was given two choices: 1) immediate death, and 2) a gamble 
in which there was a probability (“p”) of living in perfect health and a 
probability (“1-p”) of living in the health state under evaluation. The 
utility score (Ui) was then equal to 1) -p/(1 - p), where p was the 
probability when the patient was indifferent to the two choices, or 2) –(p 
+ 2.5%)/(1 - (p + 2.5%)), where p was the probability when the patient 
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kept his previous choice even if the probabilities were shifted [146]. As 
the lowest possible utility score calculated in this way was -39 (i.e., 
solving the equation: 0 = 0.975 * (1) + 0.025 * utility value of the health 
state under evaluation), the distribution of utility scores could highly 
skew to the low end [150]. Therefore, based on the standard utility 
assessment guideline and published studies[150-152], utility scores for 
health states worse than death were further transformed to the -1 to 0 
scale using the formula Ui / (1 – Ui). 
 
As it has been found that preference for a health state can be affected 
by its duration and its subsequent health states [153], a cascading 
approach, recommended by utility assessment guidelines [120, 123, 146], 
was used to elicit utilities for short-term health states. First, raw scores of 
short-term health states were elicited on a scale anchored by perfect 
health and the worst short-term health state that was perceived by the 
patient in the previous process of ranking. It was assumed that patients 
would return to their good health after staying in a short-term health 
state for a pre-determined period. Next, the worst short-term health state 
was redefined as a health state with the same attributes and pre-
determined period but was followed by death. In this way, this redefined 
health state had the same subsequent health state (i.e., death) as long-
term health states, and its utility was elicited together with long-term 
health states on the 0 to 1 utility scale. The utility value for this redefined 
health state was equal to that for the worst short-term health state. Lastly, 
utility values for the remaining short-term health states were obtained by 
converting their raw scores to the 0 to 1 utility scale, using the formula: x 
+ (1 - x) * Uw, where x and Uw denoted the raw score of the short-term 
health state under evaluation, and the utility value of the worst short-






The validity of SG- and VAS-derived utility scores was assessed by 
logical consistency:  whether the order of utility values corresponded to 
the levels of morbidities associated with each health state. It was 
hypothesized a priori that (1) the mean utility scores of “well on 
warfarin”, “well on dabigatran”, “well on rivaroxaban” and current health 
state were higher than those of major ischemic stroke, minor ischemic 
stroke and ICH; (2) the mean utility scores of major ischemic stroke and 
ICH were lower than those of minor ischemic stroke and TIA; and (3) the 




Descriptive statistics were used to describe patients’ demographic 
and clinical characteristics. Pearson Chi-Square test and independent 
sample t-test were used to compare the demographic and clinical 
characteristics of respondents and non-respondents, where appropriate. 
Wilcoxon signed-rank test was used to compare the utility scores elicited 
by the SG and VAS. Due to the skewness of the values elicited by the SG, 
the logical consistency of the SG was assessed using Wilcoxon signed-rank 
test. The logical consistency of the VAS was assessed by the paired-sample 
t test. All analyses were performed using SPSS version 19.0. The level of 






A total of 186 patients were approached, and 100 patients agreed to 
participate in the survey and completed the questionnaire, giving a 
response rate of 53.8%. Respondents’ and non-respondents’ 
characteristics are summarized in Table 5.1. Respondents had a mean ± 
SD age of 53.3 ± 12.7 years and had been taking warfarin for a mean ± SD 
duration of 7.8 ± 7.4 years. More than half of the respondents were male 
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(58.0%), Chinese (62.0%), married (71.0%), spoke English (66.0%), and 
had completed secondary or post-secondary education (79.0%). The most 
common indications for warfarin were AF and DVT (64.0%). Non-
respondents were older (p = 0.005) and more likely to have AF (p = 0.01). 
The most common reasons for non-participation were lack of time 





Table 5.1 Patients’ demographic and clinical characteristics (Chapter 5) 
Characteristics 
Respondents 
(n = 100) 
Non-respondents 
(n = 86) 
p value 
 n (%)a  
Gender  0.30 
Male 58 (58.0) 43 (50.0)  
Female 42 (42.0) 43 (50.0)  
Ethnicity  0.16 
Chinese 62 (62.0) 65 (75.6)  
Malay 19 (19.0) 12 (14.0)  
Indian 11 (11.0) 7 (8.1)  
Others 8 (8.0) 2 (2.3)  
Language  0.07 
English 66 (66.0) 45 (52.3)  
Chinese 34 (34.0) 41 (47.7)  
Educational level  NA 
 No school or primary 18 (18.0) NA  
Secondary 39 (39.0) NA  
Post-secondary 40 (40.0) NA  
Marital status NA 
Married 71 (71.0) NA  
Not married 29 (29.0) NA  
Indication for warfarin 0.01 
AF 10 (10.0) 23 (26.7)  
DVT 54 (54.0) 37 (43.0)  
Others 36 (36.0) 26 (30.2)  
TTR in the past 3 months (%) 0.10 
< 80 50 (50.0) 54 (62.8)  
≥ 80 50 (50.0) 32 (37.2)  
 mean ± SD  
Age (years) 53.3 ± 12.7 59.0 ± 14.4 0.005 
Years for taking warfarin  7.8 ± 7.4 NA NA 
a. Percentage may not add up to 100% due to missing values. 
AF = atrial fibrillation, DVT = deep vein thrombosis, NA = not available, SD 
= standard deviation, TTR = time in the therapeutic range. 
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Utility assessment  
 
The English and Chinese versions of the questionnaire were 
combined in the analyses as their utility values were comparable. The 
mean ± SD utility values for each health state are presented in Table 5.2, 
with the utility values below zero kept either as a negative value or 
rounded up to zero. Distributions of utility values elicited by the VAS and 
SG for each health state are shown in Appendix 5.8. As indicated by the 
SD, greater variation in utility scores was observed among the health 
states with a lower mean utility score. Utility values elicited by the SG 
were either positively or negatively skewed and were significantly higher 
than the VAS-derived utilities for most health states assessed. When the 
SG was used, the health states with the highest mean utility values were 
“well on rivaroxaban” (mean ± SD = 0.90 ± 0.15), “well on warfarin” (0.86 
± 0.17), current health state (0.86 ± 0.19) and “well on dabigatran” (0.83 ± 
0.18) whereas the health states with the lowest mean utility values were 
major ischemic stroke (-0.01 ± 0.53) and ICH (-0.09 ± 0.51). Though 
overall utility scores were lower, similar ranking of the health states was 
observed in VAS-derived scores.  
 
When the SG was used, 50% and 55% of the respondents perceived 
major ischemic stroke and ICH, respectively, to be worse than death. 
Around 13% of the respondents perceived major ECH and MI to be worse 




Good logical consistency was found for both the SG and VAS. All three 




Table 5.2 Mean ± SD utilities for health states elicited by the VAS and SG (n = 100) 
Health state VASa SGa p value VASb SGb p value 
Well on warfarin 0.70 ± 0.15 0.86 ± 0.17 <0.001 0.70 ± 0.15 0.86 ± 0.17 <0.001 
Well on dabigatran 0.66 ± 0.16 0.83 ± 0.18 <0.001 0.66 ± 0.16 0.83 ± 0.18 <0.001 
Well on rivaroxaban 0.85 ± 0.11 0.90 ± 0.15 <0.001 0.85 ± 0.11 0.90 ± 0.15 <0.001 
Major ischemic stroke 0.01 ± 0.33 -0.01 ± 0.53 0.76 0.13 ± 0.17 0.22 ± 0.30 0.002 
Minor ischemic stroke 0.37 ± 0.22 0.67 ± 0.32 <0.001 0.38 ± 0.19 0.69 ± 0.27 <0.001 
TIA 0.61 ± 0.29 0.64 ± 0.34 0.34 0.62 ± 0.26 0.65 ± 0.31 0.28 
ICH -0.09 ± 0.36 -0.09 ± 0.51 0.79 0.09 ± 0.14 0.17 ± 0.26 0.002 
Major ECH 0.29 ± 0.28 0.47 ± 0.39 <0.001 0.31 ± 0.26 0.50 ± 0.33 <0.001 
Minor ECH 0.54 ± 0.26 0.68 ± 0.31 <0.001 0.55 ± 0.25 0.69 ± 0.29 <0.001 
MI 0.37 ± 0.34 0.45 ± 0.39 0.02 0.40 ± 0.29 0.47 ± 0.35 0.03 
Current health state 0.83 ± 0.15 0.86 ± 0.19 0.02 0.83 ± 0.15 0.86 ± 0.19 0.02 
a. Utilities for health states worse than death were not rounded up to zero. 
b. Utilities for health states worse than death were rounded up to zero. 
ECH = extracranial hemorrhage, ICH = intracranial hemorrhage, MI = myocardial infarction, SD = standard deviation, SG = standard 





The aim of this study was to elicit patient-reported utilities for health 
states related to anticoagulation therapies using the SG and VAS in 
patients taking warfarin. In this study, both measures showed good 
logical consistency, indicating that they were comprehensible measures. 
However, studies have found that the VAS lacks a foundation in decision 
theory [154-156]. The VAS measures preferences under certainty and 
reflects difference in preferences. As intervals between the placements of 
health state cards on the VAS correspond to the difference in preferences 
observed by respondents, the preference values elicited by the VAS are 
susceptible to the context in which they are elicited, i.e., preference for a 
health state depends on those for other health states that are elicited 
together, and varies if other health states change. On the contrary, the SG 
is based on the axioms of EUT, which incorporates patients’ attitudes 
towards risks [121]. Because the prophylaxis of stroke involves risks of 
therapeutic failure and adverse effects, the SG may be a better measure of 
utility for anticoagulant-related outcomes than the VAS. 
 
Compared to the VAS, the SG elicited a higher mean utility value for 
most health states. This could be due to the fact that the SG involved risks 
so that a number of risk-avert respondents were more likely to stay in a 
health state under evaluation instead of taking the risk of death  [157]. 
Consistent with previous studies [115, 117, 118], in this study more than 
half of the respondents considered major ischemic stroke and ICH to be 
worse than death, indicating patients’ fear of strokes because of their 
severe impairment on quality of life.  
 
A few studies have assessed patient-reported utilities for 
anticoagulant-related health states using the SG, TTO and VAS, with a 
focus on major and minor strokes [115-119]. The mean utilities for major 
and minor ischemic strokes in this study were similar to those reported in 
a previous study, in which patients with AF were interviewed using the 
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SG, and the mean utilities for major and minor strokes were 0.19 and 
0.64, respectively [117]. Other studies, however, have reported different 
utility scores for major and minor strokes. The differences could be due to 
different measures used [157] or differences in health state descriptions. 
For example, two studies did not include inability to speak as a post-
stroke disability [116, 119], while in this study different levels of speaking 
deficits were used to describe major and minor stokes. In addition, the 
difference could be due to different study populations surveyed. For 
example, stroke survivors accounted for 30% to 50% of participants in 
two previous studies [116, 118], and it has been found that stroke 
survivors are more likely to give higher utilities than non-stroke survivors 
because they have adapted to stroke-related health states [122]. 
Respondents in this study were mostly patients who were at risk for but 
had not experienced strokes. 
 
In this study, variation in utilities for health states increased as the 
severities of health states increased. Considerable variation in patient-
reported utilities for severely impaired health states, i.e., major ischemic 
stroke and ICH, were observed, with a SD of approximately 0.5 and 0.35 in 
the SG and VAS, respectively. A number of previous studies also found 
substantial variation in utilities for major strokes [115-119]. The large 
variation observed could be due to the individual difference in attitudes 
towards gambling between staying in severely impaired health states and 
using treatments that involved risks, which indicates a need for 
individualized medical decision-making. 
 
There have been controversies on the cascading approach. The major 
reason for using the cascading approach was that utilities for a health 
state can be affected by its duration and following health state. To make 
health states with different durations and following health states 
comparable, they need to be assessed in separate batches and then 
converted to the 0 to 1 utility scale. In this way, utilities for short-term 
health states may have been underestimated compared with situations 
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when short-term health states were assessed directly on the 0 to 1 utility 
scale together with long-term health states. 
 
Most clinical trials and clinical practice guidelines related to stroke 
prophylaxis have focused on clinical outcomes (e.g., INR values and stroke 
events) while the effect of a treatment and the impact of a disease on 
patients’ quality of life may not be fully accounted for. Patient-reported 
utilities, together with objective clinical outcomes, may help patients and 
physicians make better decisions in clinical settings. The findings of this 
study can be used in future CUA for anticoagulants that assists policy-
makers to optimize the allocation of healthcare resources.  
 
This study has a few limitations. First, selection bias may have existed 
because the patients with cognitive impairment (e.g., major stroke 
survivors) were excluded from the survey. As patients with post-stroke 
disabilities are likely to be accustomed to their current health states and 
are more likely to give higher utility values to severely impaired health 
states [122], exclusion of these patients may have underestimated 
utilities. In addition, the survey was conducted in an ACC, where patients 
were more likely to have better INR control. Other patient populations 
(e.g., patients with poorer INR control in the inpatient setting) may have 
had different utilities.  
 
In conclusion, among the various hypothetical health states assessed, 
a large number of patients considered ischemic stroke and ICH to be 
worse than death, indicating their significant impact on patients’ HRQoL. 
Greater variation in patients’ preference was observed for more severely 
impaired health states. The findings of this study may assist medical 





Chapter 6 Cost-Effectiveness of Dabigatran and 
Rivaroxaban Compared with Warfarin for Stroke 




AF is the most common type of cardiac rhythm disorders [5]. The 
prevalence of AF increases as age increases, affecting approximately 10% 
of people age 80 or older [5]. Patients with AF are at a four- to five-fold 
increased risk of stroke, the second leading cause of global mortality, 
across all age groups [5]; indeed, these patients account for almost one-
fifth of stroke events [13]. The disease burden of stroke in patients with 
AF is likely to increase in Singapore because Singapore’s population has 
been aging and its life expectancy has been prolonged over the past few 
years [6]. 
 
To prevent patients with AF from experiencing stroke, 
anticoagulation is often used as a prophylactic measure. Among a few oral 
anticoagulants available, warfarin has been the most commonly used for 
more than half a century [7]. Despite its positive clinical effect on the 
prevention of systemic thromboembolism and the reduction in 
consequent mortality rate [158, 159], warfarin’s narrow therapeutic 
range and considerable variability in inter-individual responses have led 
to the occurrences of out-of-range INR values in clinical practice [7], 
subjecting patients to an increased risk of thromboembolism and 
bleeding that can lead to chronic disabilities and even death [16, 19, 20]. 
Given warfarin’s adverse effects, new oral anticoagulants such as 
dabigatran and rivaroxaban have been approved and used in several 
countries; these new drugs not only can prevent thromboembolism, but 




Dabigatran etexilate is one of the novel oral anticoagulants that 
prevent stroke in patients with AF. The efficacy and safety of dabigatran 
were assessed in the RE-LY trial [54]. It was found that, compared with 
warfarin, dabigtran 150 mg twice daily significantly reduced the risks of 
stroke or systemic embolism (relative risk = 0.65; 95% confidence 
interval = 0.52 to 0.81; p < 0.001), although it had a similar rate of major 
bleeding (relative risk = 0.93; 95% confidence interval = 0.81 to 1.07; p = 
0.31). In addition, the study found that dabigtran 110 mg twice daily was 
non-inferior to warfarin for the prevention of stroke or systemic 
embolism (relative risk = 0.90; 95% confidence interval = 0.74 to 1.10; p < 
0.001), and it significantly reduced the risk of major bleeding (relative 
risk = 0.80; 95% confidence interval = 0.70 to 0.93; p = 0.003). Moreover, 
both dabigatran 150 mg and 110 mg twice daily had a significantly lower 
risk of ICH than warfarin (relative risk = 0.41 and 0.30; 95% confidence 
interval = 0.28 to 0.60 and 0.19 to 0.45; both p < 0.001, respectively).  
 
Rivaroxaban is another novel oral anticoagulant that has been 
recently approved for the prevention of stroke in patients with AF. The 
ROCKET-AF study found that rivaroxaban was non-inferior to warfarin 
for the prevention of stroke or systemic embolism (hazard ratio = 0.79; 95% 
confidence interval = 0.65 to 0.95; p = 0.02) in the as-treated safety 
population [55]. In addition, rivaroxaban had a lower risk of ICH (hazard 
ratio = 0.67; 95% confidence interval = 0.47 to 0.93; p = 0.02) than 
warfarin, although the risks of major bleeding were similar (hazard ratio 
= 1.04; 95% confidence interval = 0.90 to 1.20; p = 0.58).  
 
Both dabigatran and rivaroxaban have been approved for use in 
Singapore; however, concerns have arisen due to their higher costs 
compared with warfarin. Given the increasing healthcare expenditures 
and budget constraints, the clinical use of novel drugs can be influenced 
by their economic impact. As such, it is important to assess the cost-
effectiveness of new drugs to testify if the benefits gained are worth the 
high costs. This study aimed to evaluate the cost-utility of dabigatran and 
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rivaroxaban compared with warfarin for the prevention of stroke in 






Four treatment strategies, i.e., dabigatran 150 mg and 110 mg twice 
daily, rivaroxaban (20 mg or 15 mg) once daily and adjusted-dose 
warfarin, were compared for the prevention of stroke in patients with AF, 
using a Markov model (Figure 6.1). A diagram that illustrates the model 
structure is shown in Figure 6.2. The base case was a hypothetical cohort 
of 65-year-old patients with newly diagnosed AF and no contraindications 
to anticoagulation [5]. The health states in the model included: well with 
AF, TIA, ischemic stroke, ICH, ECH, MI, combined events of ischemic 
stroke and ICH, and death. All patients entered the model in the “well with 
AF” health state and transitioned to other health states or remained in the 
“well with AF” state in the next cycle. A cycle length of 1 month and a time 
horizon of 20 years were used [6]. Evaluated outcomes included direct 
medical costs and QALYs. The willingness-to-pay (WTP) threshold was 
equal to Singapore’s 2012 per-capita gross domestic product, i.e., SGD 
65,000 (USD 51,842) per QALY [160], which has been recommended by 
the World Health Organization and used in previous cost-effectiveness 
studies in Singapore [161-163]. The model development and analyses 
























The four treatment options are shown on the left. “M” represents a Markov process with 7 health states. These health states are identical 
for each treatment option. All patients remain in the “well with AF” state until one of the six events occurs, which are TIA, ischemic 
stroke, ICH, ECH, MI and non-event death. The branch from “well with AF” illustrates these events. The probabilities of these events 
depend on the treatment. Branches from the other health states (not shown) have a similar structure.  
AF = atrial fibrillation, ECH = extracranial hemorrhage, ICH = intracranial hemorrhage, MI = myocardial infarction, RIND = reversible 
ischemic neurological deficit, TIA = transient ischemic attack.  
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Figure 6.2 A diagram illustrating the Markov model structure 
 
AF = atrial fibrillation, ICH = intracranial hemorrhage, RIND = reversible 






The base-case estimates for rates of clinical events while on warfarin 
(i.e., ischemic stroke, ICH, ECH and MI) were obtained from the RE-LY 
trial (Table 6.1) [54], which is the only randomized clinical trial that 
assessed the efficacy and safety of dabigatran versus warfarin. In addition, 
a number of relevant cost-effectiveness studies used the rates of clinical 
events from the RE-LY trial [164-169]. It was assumed that 28% of 
ischemic neurologic events were TIAs [165]. The range for the sensitivity 
analysis of ischemic stroke rate on warfarin was derived from published 
studies to cover the varied rates of ischemic stroke with CHADS2 scores 
ranging from 0 to 6 [54, 55, 170-172]. The ranges for sensitivity analyses 
of other parameters of warfarin used a wider range obtained from either 




The base-case estimates and ranges for the relative risks or hazard 
ratios of clinical events on dabigatran and rivaroxaban were derived from 
the RE-LY and the ROCKET-AF, respectively [54, 55]. The rate of a clinical 
event on dabigatran and rivaroxaban were derived by multiplying the 
rate of event on warfarin by the relative risk and hazard ratio of the event 
on dabigatran and rivaroxaban from the RE-LY and the ROCKET-AF, 
respectively. 
 
The percentages of clinical events with different severity levels were 
derived from published cost-effectiveness studies [165, 170]. Ischemic 
stroke was classified into four categories: fatal, major, minor and 
reversible. The rates of ischemic stroke and TIA were assumed to increase 
by 1.4-fold per decade of life [172]. We classified ICH into fatal and non-
fatal, and assumed that the rate of ICH increased by 1.97-fold per decade 
of life [173]. In addition, ECH was classified as non-fatal minor, non-fatal 
major, and fatal major. Patients with an ICH or major ECH were assumed 
to stop anticoagulation and resume the same anticoagulant after 1 month. 
Similarly, MI may be fatal and non-fatal. The rate of MI was assumed to 
increase 1.3-fold per decade of life [165, 170].  
 
Mortality rates were adjusted for age (beginning at age 65 years) 
[174]. Compared with the general population, the mortality rates 
increased 1.3-fold in patients with AF and 2.3-fold in patients with AF and 
prior stroke [175-178]. It was assumed that the event rates of other 




To calculate QALYs, quality-of-life estimates (i.e., utilities) of different 
health states (Table 6.1) were multiplied by the time spent in each state. 
To obtain the utility scores for different health states in the Markov model, 
a patient-reported survey was conducted in a group of 100 patients 
taking warfarin, using the SG technique, which has been described in 
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details in Chapter 5. The mean utility scores derived from the survey were 
used as the base-case estimates while the 10th and 90th percentiles were 
used as the ranges for sensitivity analyses to be consistent with those 
used in published cost-effectiveness studies [165, 169, 170], which used 
the 10th and 90th percentiles of utility values from the study by Gage et al. 




Costs reflected the perspective of the Singapore healthcare system. 
Therefore, only direct medical costs (i.e., costs of anticoagulation 
therapies and complications) were included (Table 6.1). Detailed cost 
data were not open to the public and not reported here. We projected the 
cost for each treatment over 20 years. Costs were inflated to 2012 SGDs 
and discounted at an annual rate of 3%. 
 
Costs of anticoagulation therapies 
 
The costs of anticoagulants under evaluation, lab tests and 
professional consultations were derived from hospital electronic 
databases of the ACC of the SGH. Frequencies of professional 
consultations in patients with AF were derived by reviewing the number 
of clinical visits in patients taking warfarin, dabigatran and rivaroxaban in 
2012. A total of 111 patients were identified and followed up throughout 
2012. Each patient’s records of weekly warfarin doses prescribed and the 
cost per warfarin dose were obtained from the hospital databases to 
calculate the average monthly cost of warfarin. Dabigatran and 
rivaroxaban are taken twice and once daily, respectively. The cost of a 
dabigatran (110 mg and 150 mg) or rivaroxaban tablet is fixed, i.e., SGD 
3.36 and 5.80, respectively. Therefore, the monthly costs of dabigatran 
and rivaroxaban can be obtained. Due to the unavailability of data, the 
ranges for costs of dabigatran and rivaroxaban were estimated by 
applying the same ratio to the corresponding base-case values as the 
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monthly cost of warfarin, i.e., ±40% of the base-case values, which was 
consistent with a few published cost-effectiveness studies of oral 
anticoagulants that used ±20% to ±50% of base-case values [167, 179, 
180]. 
 
Patients taking warfarin had an average of two physician visits and 
one pharmacist visit in the initiation phase (i.e., 1st month), and a 
physician visit every six months and a pharmacist visit every two months 
in the maintenance phase. On average, patients had an INR test during 
every visit. Patients taking dabigatran had an average of one physician 
visit in the initiation phase (i.e., 1st month), and one physician visit every 
three months in the maintenance phase. Patients taking rivaroxaban had 
an average of one physician visit in the initiation phase (i.e., 1st month), 
and one physician visit every two months in the maintenance phase. On 
average, patients taking dabigatran or rivaroxaban had a full blood count 
test and a creatinine clearance test during every visit. 
 
Costs of complications 
 
One-time costs of ischemic stroke, TIA, ICH, ECH and MI were 
estimated based on the costs of hospitalization of the patients in the 
corresponding diagnosis-related groups in the ACC of the SGH in the past 
10 years, including facility costs for hospitalization, professional costs for 
a surgeon and anesthetist, and costs for drugs and lab tests (e.g., magnetic 
resonance imaging and x-ray) due to the complications. The monthly cost 
of ischemic stroke and ICH was estimated based on the costs of 
rehabilitation services of the SGH. The value of the fixed cost of a visit to 
the rehabilitation services center was collected from the hospital 
database. The average monthly frequency of visits was estimated based 






One-way sensitivity analyses were performed on all variables 
included in the model over a set of plausible ranges that were determined 
a priori (Table 6.1). Two-way analyses were performed over the 
combinations of utility for rivaroxaban, cost of rivaroxaban, and risks of 
ischemic stroke and ICH. To evaluate the impact of the uncertainty in all 
the variables simultaneously, a probabilistic sensitivity analysis was 
performed using a Monte Carlo simulation with 10,000 iterations. We 
assumed a log-normal distribution for event rates, a beta or dirichlet 
distribution for percentage parameters, a beta distribution for utilities, 




Table 6.1 Base-case values and ranges used in sensitivity analyses 




    Rate of ischemic stroke on warfarin (per 100 patient-years) 1.21 0.61 - 5.82 [54, 55, 170-172] 
    Relative risk of ischemic stroke [54] 
        Dabigatran 110 mg versus warfarin 1.11 0.88 - 1.39  
        Dabigatran 150 mg versus warfarin 0.76 0.59 - 0.97  
    Hazard ratio of ischemic stroke [55] 
        Rivaroxaban versus warfarin 0.94 0.75 - 1.17  
    Percentage of ischemic stroke on warfarin, dabigatran or rivaroxaban (%) [165] 
        Fatal (within 30 days) 8.20 5.50 - 10.90  
        Major 40.20 35.30 - 45.10  
        Minor 42.50 37.60 - 47.40  
        Reversible 9.10 NA  
  ICH 
    Rate of ICH on warfarin (per 100 patient-years) 0.76 0.59 - 0.90 [54, 55, 170] 
    Relative risk of ICH [54] 
        Dabigatran 110 mg versus warfarin 0.30 0.19 - 0.45  
        Dabigatran 150 mg versus warfarin 0.41 0.28 - 0.60  
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Table 6.1 Base-case values and ranges used in sensitivity analyses (Continued) 
Variable Base-case value Range References 
    Hazard ratio of ICH [55] 
        Rivaroxaban versus warfarin 0.67 0.47 - 0.93  
    Percentage of ICH on warfarin, dabigatran or rivaroxaban (%) [170, 181] 
        Fatal (within 30 days) 36.4 28.30 - 45.20  
        Non-fatal 63.6 NA  
ECH 
    Rate of ECH on warfarin (per 100 patient-years) 2.84 2.35 - 2.93 [54, 170] 
    Relative risk of ECH [54] 
        Dabigatran 110 mg versus warfarin 0.94 0.81 - 1.10  
        Dabigatran 150 mg versus warfarin 1.07 0.92 - 1.24  
    Hazard ratio of ECH [170] 
        Rivaroxaban versus warfarin 1.04 0.90 - 1.20  
    Rate of minor ECH on warfarin (per 100 patient-years) 16.37 10.0 - 17.0 [54, 55, 165, 170] 
    Relative risk of minor ECH [54] 
        Dabigatran 110 mg versus warfarin 0.79 0.74 - 0.84  




Table 6.1 Base-case values and ranges used in sensitivity analyses (Continued) 
Variable Base-case value Range References 
    Hazard ratio of minor ECH [55] 
        Rivaroxaban versus warfarin 1.04 0.96 - 1.13  
    Percentage of major ECH on warfarin, dabigatran or rivaroxaban (%) [170] 
        Fatal (within 30 days) 1.47 1.00 - 4.00  
        Non-fatal 98.53 NA  
MI 
    Rate of MI on warfarin (per 100 patient-years) 0.64 0.51 - 1.31 [55, 169, 170, 182] 
    Relative risk of MI [54] 
        Dabigatran 110 mg versus warfarin 1.29 0.96 - 1.75  
        Dabigatran 150 mg versus warfarin 1.27 0.94 - 1.71  
    Hazard ratio of MI [55] 
        Rivaroxaban versus warfarin 0.81 0.63 - 1.06  
    Percentage of MI on warfarin, dabigatran or rivaroxaban (%) [170, 183] 
        Fatal (within 30 days) 16.60 15.80 - 17.40  





Table 6.1 Base-case values and ranges used in sensitivity analyses (Continued) 
Variable Base-case value Range References 
Death 
    Relative risk of non-event death 
        NVAF 1.30 1.00 - 1.50 [175-177] 
        NVAF and prior stroke 2.30 1.30 - 3.00 [178] 
Quality-of-life estimates (utilities) Patient survey 
    Healthy (i.e., AF without a stroke or bleed)  
        Warfarin 0.86 0.63 - 0.98  
        Dabigatran 0.83 0.58 - 0.98  
        Rivaroxaban 0.90 0.73 - 0.98  
    Ischemic stroke  
        Major deficit 0.22 0.00 - 0.68  
        Minor deficit 0.69 0.29 - 0.98  
    Bleeding  
        ICH 0.17 0.00 - 0.62  
        Major ECH 0.50 0.00 - 0.90  




Table 6.1 Base-case values and ranges used in sensitivity analyses (Continued) 
Variable Base-case value Range References 
    TIA 0.65 0.05 - 0.97  
    MI 0.47 0.00 - 0.92  
Costs Hospital databases 
    Monthly cost of anticoagulant, SGD  
        Warfarin 9.06 4.72 - 13.25  
        Dabigatran 204.54 122.72 - 286.36  
        Rivaroxaban 176.54 105.92 - 247.15  
    Cost of INR test, SGD 13.30 NA  
    Cost of full blood count and creatinine clearance tests, SGD 32.30 NA  
    Cost of physician consultation, SGD 71.00 NA  
    Cost of pharmacist consultation, SGD 21.60 NA  
    One-time cost of neurological event, SGD  
        Major ischemic stroke 11,147.47 7,719.63 - 17,267.90  
        Minor ischemic stroke 3,420.68 1,710.28 - 5,561.95  
        TIA 2,152.74 1,587.85 - 2,717.64  




Table 6.1 Base-case values and ranges used in sensitivity analyses (Continued) 
Variable Base-case value Range References 
    One-time cost of other events, SGD  
        Major ECH 4,480.66 3,175.24 - 15,064.04  
        Minor ECH 3,804.30 1,696.42 - 5,959.19  
        MI 4,018.00 565.00 - 8,317.00  
    Monthly cost of ischemic stroke and ICH, SGD 1,634.69 937.76 - 2,331.62 
Hospital database 
and expert opinions 
AF = atrial fibrillation, ECH = extracranial hemorrhage, ICH = intracranial hemorrhage, INR = International Normalized Ratio, MI = 













The 5-year cumulative probabilities of ischemic stroke and ICH on 
warfarin projected by the model (4.7% and 2.0%, respectively) were 
comparable to those reported from the Atrial Fibrillation Follow-up 
Investigation of Rhythm Management study with more than 4000 patients 
with AF [184], which reported  the probabilities of ischemic stroke and 




The base-case analysis showed that the quality-adjusted life 
expectancy was 8.67 QALYs with warfarin, 8.64 QALYs with dabigatran 
110 mg, 8.74 QALYs with dabigatran 150 mg and 9.24 QALYs with 
rivaroxaban (Table 6.2). The total costs were SGD 34,076.97 for warfarin, 
SGD 55,615.45 for dabigatran 110 mg, SGD 51,261.36 for dabigatran 150 
mg and SGD 54,950.41 for rivaroxaban. Dabigatran 100 mg gained fewer 
QALYs but cost more than rivaroxaban, and therefore it was dominated. 
The incremental cost-effectiveness ratio (ICER) of dabigatran 150 mg 
versus warfarin was SGD 254,492.45 (USD 202,976.91) per QALY 
whereas the ICER of rivaroxaban versus warfarin was SGD 36,231.02 
(USD 28,896.97) per QALY. Therefore, rivaroxaban had extended 
dominance over dabigatran 150 mg. Extended dominance is a method to 
eliminate from consideration a strategy (i.e., dabigatran 150 mg in this 
study), when a mixed strategy of two other alternatives (i.e., a proportion 
of patients are given rivaroxaban and other patients are given warfarin) 
can gain the same or more QALYs with a lower or same cost (Figure 6.3) 
[185]. Using a WTP threshold of SGD 65,000 (USD 51,842) per QALY, 




Table 6.2 Projected costs, QALYs and ICERs in base-case analysis 








Incremental cost per QALY gained,  
SGD/QALY (USD/QALY) 
ICER of a novel anticoagulant 
versus warfarin 
Sequential ICER 
Warfarin 34,076.97 NA 8.67 NA NA NA 
Dabigatran 
(150 mg) 
51,261.36 17,184.39 8.74 0.07 254,492.45 (203,528.81)  Extended dominance 
Rivaroxaban 54,950.41 3,689.05 9.24 0.51 36,231.02 (28,975.54) 36,231.02 (28,975.54) 
Dabigatran 
(110 mg) 
55,615.45 665.04 8.64 -0.60 Dominated Dominated 





Figure 6.3 Extended dominance of rivaroxaban over dabigatran 150 mg  
 




One-way sensitivity analyses 
 
One-way sensitivity analyses showed that a few variables greatly 
influenced the cost-effectiveness of rivaroxaban versus warfarin, 
including utilities for rivaroxaban and warfarin, monthly cost of 
rivaroxaban, and hazard ratios of ischemic stroke and ICH on rivaroxaban 
(Figure 6.4). A detailed report of the impact of these factors is provided 
below. Sensitivity analyses of other variables in the model found that the 
ICER of rivaroxaban versus warfarin varied by less than SGD 7,100 (USD 
5,663) per QALY and remained less than SGD 45,000 (USD 35,891) per 
QALY. 
 
The model was most sensitive to the utility for rivaroxaban. At a 
utility value lower than 0.85, rivaroxaban was dominated by dabigatran 
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150 mg. At a utility value higher than 0.87, the ICER of rivaroxaban versus 
warfarin was lower than SGD 65,000 (USD 51,842) per QALY. In addition, 
the utility for warfarin also influenced the ICERs to a great extent. At a 
utility value higher than 0.83, the ICER of dabigatran 150 mg versus 
warfarin exceeded SGD 65,000 (USD 51,842) per QALY. At a utility value 
higher than 0.89, the ICER of rivaroxaban versus warfarin exceeded SGD 
65,000 (USD 51,842) per QALY. At a utility value higher than 0.92, 
warfarin was the optimal choice. Dabigatran 110 mg was dominated over 
the entire range. Moreover, when the monthly cost of rivaroxaban was 
higher than SGD 240, the ICER of rivaroxaban versus warfarin exceeded 
SGD 65,000 (USD 51,842) per QALY. 
 
The model was also sensitive to the hazard ratios of ischemic stroke 
and ICH on rivaroxaban. When the hazard ratio of ischemic stroke was 
varied over the plausible range, the ICER of rivaroxaban versus warfarin 
varied by less than SGD 27,000 (USD 21,535) per QALY and remained less 
than SGD 53,000 (USD 42,271) per QALY. When the hazard ratio of ICH on 
rivaroxaban was varied over the plausible range, the ICER of rivaroxaban 
versus warfarin varied by less than SGD 23,200 (USD 18,504) per QALY 




Figure 6.4 One-way sensitivity analyses on variables that most influenced the incremental cost-effectiveness of rivaroxaban versus 
warfarin  
 
Bars indicate cost per QALY of rivaroxaban versus warfarin over the plausible ranges for variables. Upper and lower limits of variables 
evaluated in the sensitivity analyses are indicated at the two ends of the bars. The dotted line represents the cost-effectiveness 
threshold of SGD 65,000 (USD 51,842) per QALY.  
ICER = incremental cost-effectiveness ratio, ICH = intracranial hemorrhage, QALY = quality-adjusted life year, SGD = Singapore dollar. 
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Two-way sensitivity analyses 
 
Two-way sensitivity analyses were performed on the different 
combinations of key variables, including utility for rivaroxaban, cost of 
rivaroxaban and risks of ischemic stroke and ICH on anticoagulants. It 
was found that the ICER for rivaroxaban became less favorable as the 
hazard ratios of ischemic stroke and ICH on rivaroxaban increased 
together (Figure 6.5). It was also found that, with a low utility for 
rivaroxaban and a low rate of ischemic stroke on warfarin, warfarin was 
the optimal therapy while dabigatran 150 mg was favored as the rate of 
ischemic stroke on warfarin increased (Figure 6.6). In addition, as the cost 
of rivaroxaban increased, warfarin was the optimal therapy for patients 
with a low rate of ischemic stroke on warfarin, and dabigatran 150 mg 
was the optimal therapy for patients with a high rate of ischemic stroke 
on warfarin (Figure 6.7). 
 
Probabilistic sensitivity analysis 
 
In the Monte Carlo simulation that varied all variables simultaneously, 
rivaroxaban and warfarin were cost-effective in 91.29% and 8.05% of the 
10,000 iterations, respectively, using a WTP threshold of SGD 65,000 
(USD 51,842) per QALY. In addition, rivaroxaban was cost-effective in 
98.64% of the 10,000 iterations, using a WTP threshold of SGD 130,000 





Figure 6.5 Two-way sensitivity analyses on the incremental cost-
effectiveness of rivaroxaban versus warfarin (hazard ratios of ischemic 











ICH = intracranial hemorrhage. 
 
Figure 6.6 Two-way sensitivity analyses on the incremental cost-
effectiveness of rivaroxaban versus warfarin (utility for rivaroxaban and 









Figure 6.7 Two-way sensitivity analyses on the incremental cost-
effectiveness of rivaroxaban versus warfarin (monthly cost of rivaroxaban 











SGD = Singapore dollar. 
 













The dotted line represents the cost-effectiveness threshold of SGD 65,000 
(USD 51,842) per QALY.  





In the base-case analysis, dabigatran was dominated and rivaroxaban 
was a cost-effective therapy compared with warfarin, using a WTP 
threshold of SGD 65,000 (USD 51,842) per QALY. The robustness of the 
results was further confirmed by the probabilistic sensitivity analysis 
over a wide range of the model inputs. However, the cost-effectiveness of 
rivaroxaban versus warfarin was sensitive to a few parameters, including 
cost of rivaroxaban, and utilities for rivaroxaban and warfarin.  
 
In this study, the ICER of rivaroxaban versus warfarin was SGD 
36,231.02 (USD 28,896.97) per QALY, which was below the WTP 
threshold of SGD 65,000 (USD 51,842) per QALY. In addition, rivaroxaban 
was cost-effective in more than 90% of the Monte Carlo simulations. The 
findings were similar to those reported in Lee et al. [170], which found 
that the ICER of rivaroxaban versus warfarin was USD 27,498 per QALY 
and that rivaroxaban was cost-effective in 80.1% and 91.4% of the Monte 
Carlo simulations, using a WTP threshold of USD 50,000 and USD 100,000 
per QALY, respectively. In another study, Harrington et al. [166] evaluated 
the cost-effectiveness of rivaroxaban, dabigatran and apixaiban versus 
warfarin. It was found that rivaroxaban was cost-effective compared with 
warfarin, and had an ICER of USD 3,190/ QALY in the base-case analysis, 
which was much lower than that found in the present study. One 
explanation could be that Harrington et al. included costs of patient time 
for clinical visits in the estimation of the total costs of oral anticoagulation 
therapies, as the study adapted a societal perspective. As the annual cost 
of patient time spent on INR tests for warfarin (i.e., USD 1,750.92) was 
much higher than that for other oral anticoagulants (i.e., USD 229.36), the 
difference in costs between warfarin and other anticoagulant therapies 
was reduced, which may have decreased the ICER of rivaroxaban versus 
warfarin. Another explanation could be the differences in clinical inputs 
used in the models. For example, compared with the hazard ratio of ICH 
on rivaroxaban versus warfarin in the present study (i.e., hazard ratio = 
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0.67), Harrington et al. used a lower value (i.e., hazard ratio = 0.59), which 
favored the use of rivaroxaban.  
 
Furthermore, in the probabilistic sensitivity analysis of Harrington et 
al. [166], rivaroxaban was the optimal treatment strategy in only 14.9% 
and 4.4% of the Monte Carlo simulations using a WTP threshold of USD 
50,000 and USD 100,000 per QALY, respectively. One explanation of the 
low probabilities could be the inclusion of apixaban, which had lower 
rates of all adverse events than rivaroxaban in the model. Therefore, the 
probability of rivaroxaban being the optimal strategy was reduced. 
Another explanation could be the differences in utilities used for 
anticoagulants. In the present study, the utility score of dabigatran (i.e., 
base-case value = 0.83; sensitivity range = 0.58 to 0.98) was lower than 
that of rivaroxaban (base-case value = 0.90; sensitivity range = 0.73 to 
0.98). However, in the study by Harrington et al., dabigatran was assumed 
to have the same utility as rivaroxaban (i.e., decrement in utility for 
anticoagulation in the base case = - 0.0105; sensitivity range = -0.0110 to -
0.0090), which further reduced the probability of rivaroxaban being the 
optimal strategy. 
 
The findings of deterministic sensitivity analyses in this study were 
also similar to those reported by Lee et al. [170]. The risk of ischemic 
stroke on warfarin did not affect the cost-effectiveness of rivaroxaban 
versus warfarin. The ICER was primarily driven by the cost of rivaroxaban. 
As the cost of rivaroxaban increased, the ICER of rivaroxaban versus 
warfarin exceeded the WTP threshold of SGD 65,000 (USD 51,842) per 
QALY. Moreover, it was found in a two-way sensitivity analysis that 
rivaroxaban was dominated by warfarin, when the hazard ratios of 
ischemic stroke and ICH on rivaroxaban were both high.  
 
A few previous studies found that dabigatran was another cost-
effective anticoagulant compared with warfarin [165, 166, 168, 186]. For 
example, Freeman et al. [165] found that the ICER of dabigatran 150 mg 
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versus warfarin was USD 45,372 per QALY and that high-dose dabigatran 
was the optimal therapy in more than 50% of the Monte Carlo simulations, 
using a WTP threshold of USD 50,000 or USD 100,000. Despite the similar 
model used in the present study, it was found that dabigatran 150 mg and 
110 mg were dominated. One explanation for the differences in the 
results derived could be that the local utilities used in this study were 
different from those used in previous studies [115]. To be specific, when 
eliciting the utility for dabigatran, the study participants were asked to 
consider dyspepsia as an adverse effect of dabigatran, which may have led 
to the lower mean utility for dabigatran and favored the use of warfarin. 
On the contrary, in previous studies, the utility for dabigatran was elicited 
by expert opinions [187] and the utility derived (i.e., 0.994) was higher 
than that for warfarin (i.e., 0.987), which may have favored the use of 
dabigatran. Another explanation could be the difference in event rates. 
The present study used a higher rate of major ECH for taking dabigatran 
150 mg than that for taking warfarin, which favored the use of warfarin, 
whereas in Freeman et al. [165], the annual rate of major ECH for taking 
dabigatran 150 mg was assumed to be the same as that of major 
hemorrhage (i.e., 3.11), which was lower than that of warfarin (i.e., 3.36). 
It could also be due to the different perspectives that were adapted, which 
led to different compositions of costs (e.g., the inclusion of the costs of 
patient time).  
 
The values of clinical parameters in this model were extracted from 
the RE-LY and the ROCKET-AF. Differences in the clinical characteristics 
of participants such as CHADS2 scores and TTR in the two trials 
challenged the cross-trial comparison, as patients with different clinical 
characteristics may have had different rates of clinical events. Previous 
cost-effectiveness studies that compared several novel oral 
anticoagulants with warfarin used pooled clinical data from clinical trials 
for the base-case analysis [166, 186]. In this study, the base-case analysis 
used clinical data derived from the RE-LY whereas the clinical data from 
the ROCKET-AF were used only when the data from the RE-LY were not 
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available. This decision was made because the average TTR of 
participants in the RE-LY was very close to the mean TTR of patients from 
whom the cost and utility data were derived in this study. Moreover, the 
clinical parameter values derived from the RE-LY were comparable to 
those used in previous cost-effectiveness studies [166, 186].  
 
This study has several limitations. First of all, the rates of clinical 
events in the model were derived from clinical trials, which may have 
overestimated the efficacy and safety of therapies because participants 
enrolled in the trials may have had higher medication adherence and 
more intensive monitoring than patients in general practice. Second, the 
rates of clinical events were derived from clinical trials with a median 
follow-up of approximately two years and extrapolated over 20 years. 
Nevertheless, the rates of clinical events may vary over time. Third, the 
starting age of the cohort in this study was 65 years, which was lower 
than the mean age of patients in the RE-LY trial (i.e., 71 years). As several 
event rates (e.g., ischemic stroke and ICH) increase as age increases, the 
event rates used in the model may have been inflated. Fourth, the event 
rates used in this study were from the trials conducted in western 
populations. Whether they can be generalized to Asian populations 
remains unknown. Last, the costs of complications were derived from 
patients in an ACC and may not be generalizable to patients in an 
inpatient setting. However, as the study focused on the incremental cost-
effectiveness of therapies, its results may not have been significantly 
impacted by the use of complication costs from a single healthcare setting.  
 
In conclusion, this study found that rivaroxaban was a cost-effective 
therapy compared with warfarin for the prevention of stroke in patients 
with AF. Dabigatran was dominated in the base-case analysis. The results 
were further confirmed in the probabilistic sensitivity analysis. The 









The first study of this thesis project examined the psychometric 
properties of the 8-item MMAS in patients taking warfarin and found that 
the scale had moderate reliability, good criterion-related validity and 
good construct validity. The confirmatory factor analysis showed that the 
8-item MMAS was unidimensional, and all except one of the hypotheses 
were fulfilled. In addition, the scale was found to have high sensitivity for 
identifying non-adherent patients.  
 
In the second study, three commonly used medication adherence 
measures were compared in patients taking warfarin in Singapore: the 8-
item MMAS, VAS, and MRA. This study found that most participants were 
considered adherent by all three measures. The MMAS was associated 
with both the VAS and the MRA whereas no association was found 
between the VAS and the MRA. In addition, the MRA was found to be 
associated with most of the INR measures, including the percentage of 
TTR in the past 2 weeks and 3 months, and the percentage of INRs in the 
therapeutic range in the past 2 weeks. The MMAS was only associated 
with the percentage of INRs in the therapeutic range in the past 2 weeks, 
and the VAS was not associated with any INR measures. Therefore, the 
MRA might be more suitable for measuring medication adherence to 
warfarin than the MMAS and the VAS. 
 
The third study assessed patient-reported knowledge, satisfaction 
and concerns regarding warfarin therapy, and their associations with 
medication adherence and INR control. Patients’ medication adherence 
was assessed using the MRA, based on the findings of the second study. It 
was found that patients had high medication adherence, moderate 
knowledge, moderate satisfaction, and few concerns regarding warfarin 
therapy. Moreover, it was found that 1) higher satisfaction was associated 
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with better knowledge and fewer concerns, 2) higher satisfaction and 
better knowledge were associated with higher warfarin refill adherence, 
and 3) better knowledge, fewer concerns, higher satisfaction and higher 
warfarin adherence were associated with better INR control.  
 
In order to achieve the second objective of this project, the fourth 
study assessed patients’ utilities for health states related to 
anticoagulation therapies. It was found that ischemic stroke and ICH had a 
significant impact on patients’ HRQoL and that there was a large variation 
in patients’ utilities for these two health states.  
 
The last study evaluated the CUA of dabigatran and rivaroxaban 
compared with warfarin in patients with AF in Singapore, incorporating 
the utility values derived from the fourth study. In the base-case analysis, 
it was found that rivaroxaban was a cost-effective therapy compared with 
warfarin, and had extended dominance over dabigatran 150 mg. 
Dabigatran 110 mg was also dominated. A probabilistic sensitivity 





This thesis had five major contributions to the field of patient-
reported outcomes and pharmacoeconomics of patients taking 
anticoagulants. First, to the best of our knowledge, this thesis was the first 
to evaluate the psychometric properties of the 8-item MMAS in patients 
taking oral anticoagulants. It provided important justification for the 
future development and revision of patient-reported, anticoagulant-
specific medication adherence measures. Second, this thesis compared 
three commonly used medication adherence measures. The findings can 
help healthcare providers to select the most suitable measure to assess 
medication adherence in patients taking anticoagulants. Third, this thesis 
revealed patients’ concerns and deficits in knowledge and satisfaction 
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regarding warfarin therapy. The findings provided healthcare providers 
with critical information that can help them effectively develop patient-
targeted education. Fourth, this thesis was the first to assess patient-
reported utilities for health states related to oral anticoagulation 
therapies in an Asian population. The findings were essential to the 
evaluation of anticoagulant-related cost-effectiveness analyses in not only 
Singapore’s population, but also other Asian populations. Lastly, this 
thesis evaluated the cost-utility of dabigatran and rivaroxaban compared 
with warfarin in patients with AF. These findings are important to the 
decision-making of healthcare providers. 
 
Major Limitations  
 
The limitations of the studies in this thesis have been discussed in 
each individual chapter and are briefly summarized here. First of all, 
participants in these studies were recruited from an outpatient ACC. 
Therefore, the findings may not be generalizable to inpatients or other 
ambulatory patients, who may have poorer INR control. Second, selection 
bias may have existed due to the convenience sampling procedure used in 
the survey studies. For example, patients who were non-adherent to 
warfarin were also more likely to miss their appointments with the ACC 
pharmacists or to have passed away as a consequence of non-adherence-
induced complications prior to the surveys. Therefore, the medication 
adherence measured may have been inflated. Third, the MMAS and 
satisfaction scores may have been affected by social desirability and recall 
bias, which may have overestimated the actual medication adherence and 
satisfaction regarding warfarin therapy. Lastly, the rates of clinical events 
in the model used in the CUA were derived from clinical trials and may 
have been overestimated due to the higher medication adherence and 
more intensive monitoring in patients enrolled in the trials than patients 
in real practice. In addition, the rates from clinical trials with a median 
follow-up of approximately two years were extrapolated over 20 years, 




Future Studies  
 
Based on the major findings and limitations of the studies in this 
thesis, a few new research questions have been raised and need to be 
investigated in future studies. First, as the 8-item MMAS is a generic 
measure, it does not include a few important domains of medication 
adherence to oral anticoagulants such as if the patient takes warfarin at a 
regular time each day and if the patient takes the dosage exactly as 
prescribed. As a scale composed of anticoagulant-specific questions is 
more likely to have better reliability and validity than a generic measure, 
an oral anticoagulant-specific medication adherence measure that is easy 
to incorporate into a clinical visit needs to be developed. 
 
Second, in addition to the MMAS, VAS and MRA, a few medication 
adherence measures have been used to assess patients’ adherence to 
long-term medications (e.g., the electronic monitoring system). Future 
studies can compare the MRA with other medication adherence measures 
that can be used in patients taking anticoagulants. Such comparison may 
provide a further understanding regarding which measure is the most 
suitable to assess medication adherence to oral anticoagulants in various 
clinical settings.   
 
Third, as patients’ medication adherence to long-term therapies may 
change over time, assessment of medication adherence to oral 
anticoagulants using cross-sectional surveys cannot capture its variation 
over time. Therefore, a longitudinal study is needed to evaluate the 
changes in medication adherence in the long term in order to get a better 
understanding of patients’ adherence to anticoagulants, especially in 





Fourth, based on the findings of patients’ knowledge deficits and 
concerns regarding warfarin, future studies can develop innovative, 
patient-targeted educational programs, and investigate their impact on 
INR control in patients taking oral anticoagulants, especially elder and 
poorly-educated patients who are in the greatest need of adequate 
information related to anticoagulation therapies. 
 
Fifth, the population in Singapore is composed of multi-ethnic groups, 
and the studies in this project excluded the minority groups of patients 
who spoke languages such as Malay and Tamil. To meet the demands of 
non-English and non-Chinese speaking people in Singapore, other 
language versions of the study questionnaires (e.g., knowledge scale) 
need to be developed.  
 
Lastly, several novel oral anticoagulants in addition to dabigatran and 
rivaroxaban have recently been used in several western countries, some 
of which might be used in Singapore in the near future. The cost-
effectiveness of these new oral anticoagulants such as apixaban compared 
with warfarin can be evaluated in Singapore in order to assist healthcare 
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Appendix 2.1 English Version of the Questionnaire for Chapter 2 
 
                                                                                             Survey ID No: _________ 
Survey on Warfarin/ Marevan® Use 
 
Date of survey: _____________(dd/mm/yy)      Study site: Singapore General Hospital (SGH)   
Interviewer: ___________________ 
 
Please tick the appropriate box  
 
1. What is the highest level of education that you have completed: 
   1. No school  5. Pre-U / JC    
   2. Primary  6. Polytechnic 
   3. Secondary (‘O’/’N’ Level)   7. University 
   4. ITE       
 
2. Over the past 2 weeks, how often did you follow the diet suggestions 
from your doctor or pharmacist for warfarin/Marevan® therapy (e.g., 
consume the same amount of vegetables every week)? 
 
  1. Never  4. Usually 
  2. Rarely  5. Always 
  3. Sometimes  6. Not applicable (e.g., no 
suggestion from doctors or 
pharmacists) 
 
3.  How often do you think your medication regimens for warfarin/ 
Marevan® and other medications are difficult to follow? 
  1. Never  4. Usually 
  2. Rarely  5. Always 










4. Over the past 2 weeks, how often did you take your 
warfarin/Marevan® at the same time of the day? 
 
  1. Never  4. Usually 
  2. Rarely  5. Always 
  3. Sometimes   
 
5. Over the past 2 weeks, how often did you take the dosage of 
warfarin/Marevan® exactly as prescribed by your doctor or 
pharmacist? 
  1. Never  4. Usually 
  2. Rarely  5. Always 
  3. Sometimes   
 
6-13. Thinking of the warfarin/Marevan® regimen prescribed to you by 
your doctor or pharmacist, please answer the following questions. 
Please place a tick in the box that best indicates your response to each 
item. 
Please answer the following questions honestly. Your answers will be 
kept confidential and will not have any effect on your medical care. 











8. Have you ever reduced or stopped taking your warfarin/Marevan®   
      without telling your doctor or pharmacist because you felt worse 





9. When you travel or leave home, do you sometimes forget to bring 












11. When you feel like your blood thickness (INR) is within the control  





12. Do you ever feel troublesome about sticking to your warfarin/ 





13. How often do you have difficulty remembering to take your warfarin/  
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Appendix 2.2 Chinese Version of the Questionnaire for Chapter 2 
                                                                                 调查问卷编号： ___________ 
有关华法林(warfarin)/Marevan®使用的调查 
调查日期： ___________________(日日/月月/年年)       调查地点：  新加坡中央医院   
采访者姓名： ___________________ 
请选择合适的选项。        
 
1. 你完成的最高教育文凭: 
   1. 没有正式文凭  5. ‘A’水准文凭    
   2. 小学离校考试  6. 理工学院毕业文凭 
   3. ‘O’/‘N’ 水准文凭   7. 大学文凭 
   4. 工艺学校文凭       
 
2.  在过去的 2 个星期内，你多常遵守你的医生或药师提出的华法林 
(warfarin)/Marevan®治疗饮食建议 （比如， 每个星期吃相同分量的蔬菜）？ 
 
  1. 从不  4. 通常 
  2. 很少  5. 总是 





  1. 从不  4. 通常 
  2. 很少  5. 总是 
  3. 有时   
 
4. 在过去的 2 个星期内，你多常在每天的同一个时间服用华法林 
(warfarin)/Marevan®？ 
  1. 从不  4. 通常 
  2. 很少  5. 总是 
  3. 有时   
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5. 在过去的 2 个星期内，你多常完全按照医生或药师所指示的剂量服用华法
林 (warfarin)/Marevan®？ 
  1. 从不  4. 通常 
  2. 很少  5. 总是 











7. 在过去的 2 个星期内，你是否有任何一天不曾服用华法林 (warfarin)/  
















9. 当你旅行或者离开家的时候，你会有时忘记随身携带你的华法林 (warfarin)/  


















12. 你是否有感到遵守华法林 (warfarin)/Marevan®治疗计划是一件麻烦的事 


















Appendix 2.3 Data Collection Form for Chapter 2 
 
Psychometric Properties of the 8-item MMAS in Patients Taking Warfarin  
Data Collection Forma  
Survey ID 
Number 
Language Gender Ethnicity Educational level 
Adherence to 
recommended diet 
      
      
(Continued)      
Difficulty of 
following 
Timing adherence Dosage adherence MMAS-Q1 MMAS-Q2 MMAS-Q3 
      
      
(Continued)      
MMAS-Q4 MMAS-Q5 MMAS-Q6 MMAS-Q7 MMAS-Q8 Date of survey 





(Continued)      
Date of birth Number of INR valuesb 
Number of INR values 
in the therapeutic 
rangeb 
TTR (%)b Days of supplyc Days to refillc 
      
      
(Continued)      
Indication      
      
a. All parameters correspond to warfarin therapy (also known under the brand name Marevan® ). 
b. In the past 2 weeks.  
c. In the past 3 months. 
ID = identity, INR = International Normalized Ratio, MMAS = Morisky Medication Adherence Scale, MMAS-Q = Morisky Medication 





Appendix 2.4 Data analyses of the English and Chinese versions of the 8-item MMAS 
 
Table A2.1 Responses to items of the English and Chinese versions of the MMASa 
Responses to items 
Language, n (%) 
p value 
English (n = 82) Chinese (n = 69) 
1. Do you sometimes forget to take your warfarin? 
Yes 42 (51.2) 25 (36.2) 
0.07 
No 40 (48.8) 44 (63.8) 
2. Over the past 2 weeks, were there any days when you did not take your warfarin? 
Yes 11 (13.4) 4 (5.8) 
0.12 
No 71 (86.6) 65 (94.2) 
3. Have you ever reduced or stopped taking your warfarin without telling your 
doctor or pharmacist because you felt worse when you took it? 
Yes 5 (6.1) 1 (1.4) 
0.15 
No 77 (93.9) 68 (98.6) 
4. When you travel or leave home, do you sometimes forget to bring along your 
warfarin? 
Yes 7 (8.5) 2 (2.9) 
0.15 
No 75 (91.5) 67 (97.1) 
5. Did you take your warfarin yesterday? 
Yes 2 (2.4) 0 (0.0) 
0.19 
No 80 (97.6) 69 (100.0) 
6. When you feel like your blood thickness (INR) is within the control range, do you 
sometimes stop taking your warfarin? 
Yes 4 (4.9) 0 (0.0) 
0.06 
No 78 (95.1) 69 (100.0) 
7. Do you ever feel troublesome about sticking to your warfarin regimen plan? 
Yes 22 (26.8) 24 (34.8) 
0.29 




8. How often do you have difficulty remembering to take your warfarin? 
Never 48 (58.5) 52 (75.4) 
0.02 
Rarely 22 (26.8) 15 (21.7) 
Sometimes 11 (13.4) 2 (2.9) 
Often 1 (1.2) 0 (0.0) 
Always 0 (0.0) 0 (0.0) 
a. Chi-square test was used for items 1 to 7; Mann-Whitney U test was used for item 
8. 





Figure A2.1 Distribution of the 8-item MMAS scores of the English version (n = 82) 
 
MMAS = Morisky Medication Adherence Scale. 
 
 
Median = 7.0 
Range = 1.5 to 8.0 
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No difference was found in the distributions of MMAS scores of English and Chinese 
versions (Mann-Whitney U test; p = 0.09). 
 
The English and Chinese versions had a Cronbach’s alpha of 0.63 and 0.29, 
respectively. 
 
No association was found between the MRA and MMAS scale scores of the English 
and Chinese versions (rs = 0.19 and 0.06; p = 0.09 and 0.65, respectively). 
 
Confirmatory factor analysis found that the English and Chinese versions of 8-item 
MMAS were unidimensional (both RMSEA = 0.04), and the eight items loaded well 
Median = 7.0 
Range = 5.0 to 8.0 
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Table A2.2 Hypothesis-testing of the 8-item MMAS 
Association with MMAS 
scores  
English  Chinese  
rs p value rs p value 
INRs in the therapeutic 
range (%)a 
NA 0.13 NA 0.04 
Adherence to 
recommended diet  
0.21 0.06 0.20 0.11 
Frequency of regular 
timing of warfarin therapy 
0.34 0.002 0.34 0.006 
Frequency of taking the 
dosage of warfarin exactly 
as prescribeda 
NA 0.17 NA 0.35 
Frequency of having 
difficulty following 
medication regimens 
-0.29 0.007 -0.28 0.02 
a. Mann-Whitney U test was used. 
INR = International Normalized Ratio, MMAS = Morisky Medication Adherence 




Table A2.3 Sensitivity, specificity, PPV and NPV of the English and Chinese versions 
of the 8-item MMAS 
 English Chinese 
Sensitivity (%) 72.5 73.9 
Specificity (%) 24.2 45.0 
PPV (%) 53.7 43.6 
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NPV (%) 42.1 75.0 
MMAS = Morisky Medication Adherence Scale, PPV = positive predictive value, NPV 




The sensitivity of the English and Chinese versions of the MMAS indicated that 
72.5% and 73.9% of the respondents who had poor INR control were identified as 
non-adherent to warfarin therapy, respectively, whereas the specificity indicated 
that 24.2% and 45.0% of the respondents who had good INR control were identified 
as adherent, respectively. The PPV indicated that 53.7% and 43.6% of the 
respondents who were non-adherent had poor INR control, respectively, while the 
NPV indicated that 42.1% and 75.0% of the respondents who were adherent had 










Appendix 3.1 English Version of the Questionnaire for Chapter 3 
 
                                                                                                                                            Survey ID No: ___________________ 
Survey on Warfarin/ Marevan®  Use 
 
Date of survey: ________________(dd/mm/yy)                        Study site: Singapore General Hospital (SGH)   
Interviewee’s code of role: _______________                     Interviewer: ___________________ 
 
Please tick the appropriate box  
 
1. What is the highest level of education that you have completed: 
   1. No school  5. Pre-U / JC    
   2. Primary  6. Polytechnic 
   3. Secondary (‘O’/’N’ Level)   7. University 
   4. ITE       
 
2-9. Thinking of the warfarin/Marevan®  regimen prescribed to you by your 
doctor or pharmacist, please answer the following questions. Please place a 
tick in the box that best indicates your response to each item. 
Please answer the following questions honestly. Your answers will be kept 
confidential and will not have any effect on your medical care. 





3. Over the past 2 weeks, were there any days when you did not take your  





4. Have you ever reduced or stopped taking your warfarin/Marevan®   
      without telling your doctor or pharmacist because you felt worse when       





5. When you travel or leave home, do you sometimes forget to bring along  












7. When you feel like your blood thickness (INR) is within the control  





8. Do you ever feel troublesome about sticking to your warfarin/Marevan®   





9. How often do you have difficulty remembering to take your warfarin/  
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10. Over the past 2 weeks, how often were you able to take your warfarin/ 










warfarin/Marevan®  as 
prescribed by your 
doctor or pharmacist 
Please indicate on this scale (rather like a 
thermometer), on which “always taking 
warfarin/Marevan®  as prescribed” is marked 100 and 
“never taking warfarin/Marevan®  as prescribed” is 
marked 0. 
Please do this by drawing a line from the BLACK BOX 
below to whichever point on the scale that best indicates 
how often during the past 2 weeks you were able to take 





Appendix 3.2 Chinese Version of the Questionnaire for Chapter 3 
                                                                        调查问卷编号： ___________ 
有关华法林(warfarin)/Marevan®使用的调查 
调查日期： ___________________(日日/月月/年年)       调查地点：  新加坡中央医院   
被采访者角色代码: ___________________               采访者姓名： ___________________ 
 
请选择合适的选项。        
 
1. 你完成的最高教育文凭: 
   1. 没有正式文凭  5. ‘A’水准文凭    
   2. 小学离校考试  6. 理工学院毕业文凭 
   3. ‘O’/‘N’ 水准文凭   7. 大学文凭 











3. 在过去的 2 个星期内，你是否有任何一天不曾服用华法林 (warfarin)/  





4. 你是否有在不告知你的医生或药师的情况下，减少服用或不服用华法林  
    (warfarin)/Marevan®，因为服用它让你感到更糟糕 （比如，尿中出现血、身 









5. 当你旅行或者离开家的时候，你会有时忘记随身携带你的华法林 (warfarin)/  



































10. 在过去的 2 个星期内，你多常按照医生或药师的指示服用华法林  (warfarin)/ 












































Appendix 3.3 Data Collection Form for Chapter 3 
 
Comparison of Three Medication Adherence Measures in Patients Taking Warfarin  
Data Collection Forma  
Survey ID Number Interviewee’s role Language Gender Ethnicity Educational level 
      
      
(Continued)      
MMAS-Q1 MMAS-Q2 MMAS-Q3 MMAS-Q4 MMAS-Q5 MMAS-Q6 
      
      
(Continued)      
MMAS-Q7 MMAS-Q8 VAS score 
Date of 
survey 
Date of birth 
Number of INR 
valuesb 






(Continued)      
Number of INR 
values in the 
therapeutic rangeb 
Number of INR valuesc 
Number of INR 
values in the 
therapeutic rangec 
TTR (%)b TTR (%)c Days of supplyc 
      
      
(Continued)      
Days to refillc Indication     
      
a. All parameters correspond to warfarin therapy (also known under the brand name Marevan® ). 
b. In the past 2 weeks. 
c. In the past 3 months. 
ID = identity, INR = International Normalized Ratio, MMAS-Q = Morisky Medication Adherence Scale - question, TTR = time in 
the therapeutic range, VAS = visual analogue scale. 
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Appendix 4.1 English Version of the Questionnaire for Chapter 4 
                                                                                                       Survey ID No. ___________ 
Assessment of patients’ knowledge, adherence, and satisfaction regarding warfarin 
treatment 
  
Date of survey: ______________(yyyy/mm/dd)             Interviewer: _____________ 
 
Part 1  
Please tick the appropriate box. 
1. Highest level of education: 
  1. No school 
  2. Primary 
  3. Secondary (‘O’/’N’ Level)  
  4. ITE 
  5. Pre-U / JC 
  6. Polytechnic  
  7. University or postgraduate 
 
 
2. Marital Status:     
 
  1. Never married 
  2. Currently married 
  3. Separated  
  4. Divorced 
  5. Widowed 
 
3.   Overall, approximately how many years/ months have you taken warfarin?  
       _________ years and _________ months.  
 
4. What dose of warfarin are you taking now per day? 
Color of tablets: ______________ Number of tablets: ____________ 
Color of tablets: ______________ Number of tablets: ____________ 
Color of tablets: ______________ Number of tablets: ____________ 
 
5. Do you know your target INR range?  
  1. Yes, it is: _____________ 





6. Some medicines can alter the effect of warfarin. If you are going to start 
taking a new medicine, you should: 
  1. Consult your doctor or pharmacist before taking the new medicine    
  2. Take the new medicine at a low dose and consult your doctor or  
            pharmacist at your next visit      
  3. Stop taking warfarin 
  4. Take warfarin in the morning and the new medicine in the evening 
  5. I don’t know 
 
7. Sometimes patients miss their warfarin doses. What should you do if you 
miss a warfarin dose? 
  1. If it’s 8 hours or more after your usual time for warfarin, you should  
            double the dose the next time you are supposed to take your warfarin 
  2. If it’s 8 hours or more after your usual time for warfarin, you should skip   
            the missed dose and take the next dose at usual time  
  3. If it’s less than 8 hours from your usual time for warfarin, you should   
           double the dose the next time you are supposed to take your warfarin  
  4. If it’s less than 8 hours from your usual time for warfarin, you should skip   
            the missed dose and take the next dose at usual time  
  5. I don’t know 
 
8. Which of the following medicines or supplements will NOT affect the effect 
of your warfarin? 
   1. Aspirin  
  2. Ginseng supplements  
  3. Multivitamin tablets containing vitamin K 
  4. Vitamin C 250-500mg tablets  









9. Patients taking warfarin should:  
  1. Never eat food that contains large amounts of vitamin C 
  2. Eat more green vegetables 
  3. Eat fewer green vegetables 
  4. Keep a consistent diet  
  5. I don’t know 
 
10. Which of the following statements is correct? 
  1. If you take more warfarin than prescribed, you will have an INR value   
            above the target range and an increased risk of having a blood clot   
  2. If you take more warfarin than prescribed, you will have an INR value  
            above the target range and an increased risk of bleeding  
  3. If you take less warfarin than prescribed, you will have an INR value above  
            the target range and an increased risk of having a blood clot  
  4. If you take less warfarin than prescribed, you will have an INR value below  
            the target range and an increased risk of bleeding 
  5. I don’t know 
 
11. Which of the following food will NOT affect the effect of your warfarin? 
   1. Bananas  
  2. Soybean products 
  3. Broccoli 
  4. Cauliflower 
  5. I don’t know 
 
12. As you are on warfarin, when should you monitor signs of bleeding? 
  1. When your INR value is above the target range 
  2. When you do not feel well 
  3. At all times  
  4. There is no need to monitor signs of bleeding because bleeding is not a   
           complication of warfarin 




13. Which is the symptom(s) you should look out when you are taking 
warfarin? 
  1. Blood in urine   
  2. Black and sticky stools 
  3. Unusual bruising or bleeding from gums 
  4. All of the above  
  5. I don’t know 
 
14. Which of the following statements is correct when you are taking warfarin? 
  1. You can switch different brands of warfarin as long as the dose remains  
            the same 
  2. You need to inform your dentist that you are on warfarin after having  
            dental procedures 
  3. You should avoid intramuscular (i/m) injection  
  4. If you notice unusual bleeding symptoms that are not stopping, you should  
            lie down and have a rest 
  5. I don’t know 
 
Part 2  
1. Some patients experience barriers that prevent them from taking warfarin 
as instructed by doctor or pharmacist. What has made it difficult for you to 
take warfarin? 
     (Tick all that apply.)  
  1. You forget to take warfarin  
  2. It is difficult to follow the doctors’ or pharmacists’ instructions to take  
           warfarin  
  3. Frequent visits to the hospital 
  4. Fear of the side effects of warfarin 
  5. Simultaneously taking other medicines that may alter the effect of warfarin  
  6. Restrictions on diet  
  7. Restrictions on usual activities (e.g. housework, sports, etc.)  
  8. Impact on your work 
  9. You don’t believe warfarin is helpful  
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  10. Other, please specify: __________________________ 
  11. No barriers 
 
Part 3-1  
Note: ACC refers to anticoagulation clinic. 
 Strongly 
Agree 
Agree Neutral Disagree 
Strongly 
Disagree 
1. The ACC pharmacists can 
give you useful, clear and 
sufficient instructions on 
your warfarin treatment. 
     
2. You have been given 
enough time to discuss 
with the ACC pharmacists 
during your visits. 
     
3. The ACC pharmacists are 
friendly and caring. 
     
4. Since you began your 
treatment at the ACC, you 
have felt reassured about 
your warfarin treatment. 
     
5. Since you began your 
treatment at the ACC, your 
blood thickness (INR 
results) has been better 
controlled. 
     
6. You are satisfied with 
the frequency of your ACC 
appointments at Singapore 
General Hospital for your 




7. You are satisfied with 
your waiting time in the 
ACC to see the pharmacist. 





Appendix 4.2 Chinese Version of the Questionnaire for Chapter 4 
调查问卷编号： ___________ 
病人有关华法林治疗的知识、依从和满意程度评估 
调查日期： ___________________(年年年年/月月/日日)       采访者姓名： ___________________ 
 
部分 1  
请在合适的框里打勾。  
1. 最高教育文凭： 
  1.没有正式文凭 
  2.小学离校考试 
  3.‘O’/ ’N’水准文凭 
  4.工艺学校文凭 
  5.‘A’水准文凭 
  6.理工学院毕业文凭 
  7.大学或研究生文凭 
 
2.   婚姻状况： 
  1.一直单身 
  2.目前已婚 
  3.分居 
  4.离婚 
  5.丧偶 
 
3.  总的来说，您已经吃华法林(warfarin)大约有几年或者几个月？  
     ________ 年和________ 月。                
 





5.  您知道您的正常的 INR 范围吗？ 
  1.知道，是：_____________ 






  1.在吃新药前咨询您的医生或者药剂师 
  2.吃低剂量的新药，并且在下次去医院的时候，咨询您的医生或者药剂师 
  3.停止吃华法林(warfarin) 
  4.早上吃华法林(warfarin)，傍晚吃新药 




  1.如果是在平常吃华法林(warfarin)的时间后的 8 小时才想起来，您应该在 
         下次按时吃华法林(warfarin)的时候吃双倍的剂量 
  2.如果是在平常吃华法林(warfarin)的时间后的 8 小时才想起来，您应该 
         跳过忘记吃的华法林(warfarin)，并且按时吃下一次华法林(warfarin) 
  3.如果是在平常吃华法林(warfarin)的时间 8 小时内想起来，您应该在下次 
         按时吃华法林(warfarin)的时候吃双倍的剂量 
  4.如果是在平常吃华法林(warfarin)的时间 8 小时内想起来，您应该跳过 
         忘记吃的华法林(warfarin)，并且按时吃下一次的华法林(warfarin) 
  5.不知道 
 
8.  以下哪些药或者补品不会影响华法林(warfarin)的药效？ 
  1.阿司匹林(aspirin) 
  2.人参补品 
  3.含维他命 K 的多种维生素药片 
  4.维他命 C 250-500mg 药片 











  1.从来不吃含大量维他命 C 的食物 
  2.多吃绿色蔬菜 
  3.少吃绿色蔬菜 
  4.保持规律的饮食 
  5.不知道 
 
10. 以下哪个说法是正确的？ 
  1.如果您吃的华法林(warfarin)剂量比医生开给您的剂量多，您的 INR 结果  
         就会高于正常的范围，而且血栓形成的风险增加 
  2.如果您吃的华法林(warfarin)剂量比医生开给您的剂量多，您的 INR 结果 
         就会高于正常的范围，而且出血的风险增加 
  3.如果您吃的华法林(warfarin)剂量比医生开给您的剂量少，您的 INR 结果 
         就会高于正常的范围，而且血栓形成的风险增加 
  4.如果您吃的华法林(warfarin)剂量比医生开给您的剂量少，您的 INR 结果 
         就会低于正常的范围，而且出血的风险增加 
  5.不知道 
 
11. 以下哪些食物不会影响华法林(warfarin)的药效？ 
  1.香蕉 
  2.大豆类食物 
  3.花椰菜/西篮花 
  4.菜花/花菜 











12.  由于您正在吃华法林(warfarin)，您应该在什么时候注意出血的迹象？ 
  1.当您的 INR 结果高于正常范围的时候 
  2.当您感到不舒服的时候 
  3.任何时间 
  4.不需要注意出血的迹象，因为出血不是华法林(warfarin)的并发症 
  5.不知道 
 
13. 当您在吃华法林(warfarin)的时候，您应该注意以下哪个或者哪些症状？ 
  1.血尿 
  2.黑色和黏黏的大便 
  3.不正常的瘀青或者牙龈出血 
  4.以上全部都是 
  5.不知道 
 
14. 当您在吃华法林(warfarin)的时候，以下哪个说法是正确的？ 
  1.只要剂量相同，您就可以更换不同品牌的华法林(warfarin) 
  2.您需要在牙科手术之后，告诉牙科医生您正在吃华法林(warfarin) 
  3.您应该避免肌肉注射(intramuscular injection, i/m injection) 
  4.如果您发现有不正常的出血不停止的情况，您应该躺下来休息一下 





     (请在所有合适的框里打勾。) 
  1.您忘记吃华法林(warfarin) 
  2.难以按照医生或者药剂师的指示吃华法林(warfarin) 
  3.经常去医院                                                                    
  4.担心华法林(warfarin)的副作用 
  5.同时吃其他的药，这些药有可能改变华法林(warfarin)的药效  
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  6.饮食的限制 
  7.日常活动的限制（比如，家务活、运动等） 
  8.对工作的影响                                                               
  9.您不相信吃华法林(warfarin)有帮助 
  10.其他，请说明：___________________ 
  11.没有障碍 
 
部分 3 
注释：ACC 指的是抗凝血门诊  
 非常
同意 






     
2. 看门诊时，您有足够时间与 ACC 药剂师们
讨论。 
     
3. ACC 药剂师们都是友好而且关心病人的。      
4. 自从您在 ACC 接受治疗之后，您对您的华
法林(warfarin)治疗感到放心。 
     
5. 自从您在 ACC 接受治疗之后，您的血液浓
度（INR 结果）就得到了更好的控制。 
     
6. 对于您的华法林(warfarin)治疗，您对新加
坡中央医院的 ACC 预约次数感到满意。 
     
7. 您对在 ACC 的等待看药剂师的时间感到满
意。 
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Appendix 4.3 Data Collection Form for Chapter 4 
 
Knowledge, Satisfaction, and Concerns regarding Warfarin Therapy and Their Associations with  
Warfarin Adherence and Anticoagulation Control  
Data Collection Forma 
Survey ID Number Language Gender Ethnicity Educational level Marital status 
      
      
(Continued)      












      
      
(Continued)      
KQ4 number of tablets 3 KQ5 KQ6 KQ7 KQ8 KQ9 




(Continued)      
KQ10 KQ11 KQ12 KQ13 KQ14 Concern 1 
      
      
(Continued)      
Concern 2 Concern 3 Concern 4 Concern 5 Concern 6 Concern 7 
      
      
(Continued)      
Concern 8 Concern 9 Concern 10 Concern 11 SQ1 SQ2 
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(Continued)      
SQ3 SQ4 SQ5 SQ6 SQ7 Indication 
      
      
(Continued)      
Date of survey Date of birth TTR (%)b Days of supplyc Days to refillc  
      
a. All parameters correspond to warfarin therapy. 
b. In the past 2 weeks. 
c. In the past 3 months. 







Appendix 5.1 English Version of the Questionnaire for Chapter 5 
                                                                                                       Survey ID No. ___________ 
Utility elicitation for health states related to anticoagulants 
  
Date of survey: ______________(dd/mm/yy)                             Interviewer: _____________ 
 
Part I  
Please tick the appropriate box  
        
1. What is the highest level of education that you have completed: 
   1. No school  5. Pre-U / JC    
         2. Primary 
     
 6. Polytechnic 
        3. Secondary (‘O’/’N’ Level) 
     
 7. University or postgraduate 




2. Marital Status: 
  1. Single 
 
 4. Divorced 
       2. Married 
          
 5. Widowed 
   3. Separated 
                                        
  
 
3. Overall, for approximately how many years have you taken 
warfarin/Marevan® ?  
___________ (number of years). 
 
4. Have you ever had any of the following clinical conditions? 




 Myocardial infarction (MI) 
 
None of the above 
 

















To help describe your feelings about different 
health states, i.e., how good or bad a health 
state is, we have drawn a scale (like a 
thermometer). Your most desirable health 
state is marked 100 and your least desirable 
health state is marked 0. 
We would like you to indicate your 
preference for each health state on this scale 
with a circle/arrow, in your opinion.  
You may ask the interviewer for assistance in 
this question. 
5. Visual Analogue Scale (VAS) for assessment of patient preferences  
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6. Standard gamble for assessment of patient preferences  
       The interviewer will assist you to fill up the following form. 
 





























调查日期： ___________________(日日/月月/年年)       采访者姓名： ___________________ 
                                                                                                        
 
部分 I  
请在合适的框里打勾 
        
1. 您完成的最高教育文凭是什么： 
  1. 没有正式文凭  5. ‘A’水准文凭    
  2. 小学离校考试  6. 理工学院毕业文凭 
  3. ‘O’/‘N’ 水准文凭  7. 大学或研究生文凭 
  4. 工艺学校文凭   
 
2. 婚姻状况： 
  1. 单身  4. 离婚 
  2. 已婚       5. 丧偶   
  3. 分居                                      
 




  （缺血性和出血性）中风  其他出血  以上都没有 






























6. 病人的喜好评估  




























Appendix 5.3 English Version of health state descriptions for Chapter 5 
 
Health state 1 (Perfect health)  
You do not have any physical or mental health problems. You do not have any pain 
or discomfort. 
 
Health state 2 (Immediate death) 
You die immediately. 
 
Health state 3 (Well on warfarin)  
You need to take an oral medicine once daily with occasional dose adjustments. You 
need to attend the outpatient clinic at a hospital or polyclinic about once a month for 
a blood test. You are not able to drink too much alcohol. You may bruise more easily, 
but generally you are in your good health state. 
 
Health state 4 (Well on dabigatran) 
You need to take an oral medicine twice daily with a fixed dose. You may have 
dyspepsia (i.e., stomach discomfort or burning pain), but generally you are in your 
good health state. 
 
Health state 5 (Well on rivaroxaban)  
You need to take an oral medicine once daily with a fixed dose. Generally you are in 
your good health state.  
 
Health state 6 (Ischemic stroke with major deficits)  
One side of your body is totally paralyzed and/or one side of your face droops. You 
are not able to walk or take care of yourself (e.g., bathing, dressing and feeding) 
without help. You are not able to perform most of your usual activities. Your speech 
is unclear, and people have difficulty understanding you. You find it hard to write, 




Health state 7 (Ischemic stroke with minor deficits) 
Your arm and/or leg on one side are weak and a little hard to move. You can walk, 
but with a slight limp. You can take care of yourself without help (e.g., bathing, 
dressing and feeding). You can perform most of your usual activities, but with a little 
difficulty. Your speech is a little unclear, but people understand you. You can write 
and think clearly.  
 
Health state 8 (Transient ischemic attack)  
You experience sudden numbness or weakness on one side of the body. In addition, 
you may have difficulty saying words or seeing. You may also lose your balance or 
coordination. These symptoms last for a few minutes or hours (but less than 24 
hours). You recover after that and return to your good health.  
 
Health state 9 (Intracranial bleeding)  
One side of your body is paralyzed. You experience a severe and sudden headache, 
loss of consciousness or coma (i.e., deep unconsciousness). You are not able to walk 
or take care of yourself without help (e.g., bathing, dressing and feeding). You are 
not able to perform most of your usual activities. Your speech is unclear and people 
have difficulty understanding you. You may not be able to write, memorize and/or 
think clearly.  
 
Health state 10 (Major extracranial bleeding – gastrointestinal bleeding)   
You suddenly vomit blood and/or have blood in your stool. You need an endoscopy*. 
In addition, you may need blood transfusions or an operation. You are admitted to 
hospital. You recover after two to four weeks, and you return to your good health 
with no lasting effects. 
*This is a test to look inside the body, using a flexible tube that has a small camera 
on the end of it and can be inserted through the mouth or anus, in order to identify 





Health state 11 (Minor extracranial bleeding – gastrointestinal bleeding)   
You suddenly vomit blood and/or have blood in your stool. You need an endoscopy*. 
You are admitted to hospital. You recover after two days, and you return to your 
good health with no lasting effects. 
*This is a test to look inside the body, using a flexible tube that has a small camera on 
the end of it and can be inserted through the mouth or anus, in order to identify the 
site of bleeding, stop the bleeding and prevent further bleeding.  
 
Health state 12 (Myocardial infarction) 
You may experience chest discomfort or pain, shortness of breath, and/or 
discomfort in the upper body. The discomfort or pain spreads and lasts for around 
20 minutes. You recover after that and return to your good health. However, you 
may die or have permanent heart damage if you do not go to hospital immediately. 
You need to get a number of tests at the hospital such as electrocardiogram (i.e., 
ECG*) and blood tests etc. 
*This is a test that records the heart's activity by attaching small electrodes to your 
arms, legs and chest. The test is simple and painless. 
 
Health state 13 (Current health state) 






Appendix 5.4 Chinese Version of health state descriptions for Chapter 5 
 
Health state 1 (Perfect health)  
你没有任何身体或者精神上的健康问题。你没有任何疼痛或者不舒服。 
 
Health state 2 (Immediate death) 
你会立即死亡。 
 









Health state 5 (Well on rivaroxaban)  
你需要每天吃一次剂量固定的药。大体上你处于良好的健康状态。 
 























难理解你。你可能无法写字、记忆 并且/或者 清楚地思考。 
 
Health state 10 (Major extracranial bleeding – gastrointestinal bleeding)   
你突然吐血 并且/或者 大便出血。你需要做内窥镜检查*。另外，你可能需要接受































Appendix 5.6 An example of the Chinese Version of SG chance boards for Chapter 5 
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Appendix 5.7 Data Collection Form for Chapter 5 
 
Utility Evaluation for Anticoagulant-Related Outcomes 
Data Collection Forma 
 
Survey ID Number Language Gender Ethnicity Educational level Marital status 
      
      
(Continued)      
Duration of taking 
warfarin (years) 
History of stroke History of MI 




VAS – HS1 
      
      
(Continued)      
VAS – HS2 VAS – HS3 VAS – HS4 VAS – HS5 VAS – HS6 VAS – HS7 




(Continued)      
VAS – HS8 VAS – HS9 VAS – HS10 VAS – HS11 VAS – HS12 VAS – HS13 
      
      
(Continued)      
SG – HS1 SG – HS2 SG – HS3 SG – HS4 SG – HS5 SG – HS6 
      
      
(Continued)      
SG – HS7 SG – HS8 SG – HS9 SG – HS10 SG – HS11 SG – HS12 
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(Continued)      
SG – HS13 Indication Date of survey Date of birth TTR (%)b  
      
a. All parameters correspond to warfarin therapy. 
b. In the past 3 months. 
ID = identity, MI = myocardial infarction, SG – HS = standard gamble – health state, TTR = time in the therapeutic range, VAS – 





Appendix 5.8 Distributions of SG and VAS scores for each health state in Chapter 5 
 
Figure A5.1 Utilities for “well on warfarin” elicited by the VAS 
 







Figure A5.2 Utilities for “well on warfarin” elicited by the SG 
 
 





Figure A5.3 Utilities for “well on dabigatran” elicited by the VAS 
 
 






Figure A5.4 Utilities for “well on dabigatran” elicited by the SG 
 
 






Figure A5.5 Utilities for “well on rivaroxaban” elicited by the VAS 
 
 




Figure A5.6 Utilities for “well on rivaroxaban” elicited by the SG  
 
 





Figure A5.7 Utilities for major ischemic stroke elicited by the VAS 
 
 





Figure A5.8 Utilities for major ischemic stroke elicited by the SG 
 
 




Figure A5.9 Utilities for minor ischemic stroke elicited by the VAS 
 
 




Figure A5.10 Utilities for minor ischemic stroke elicited by the SG 
 
 




Figure A5.11 Utilities for TIA elicited by the VAS 
 
 





Figure A5.12 Utilities for TIA elicited by the SG 
 
 





Figure A5.13 Utilities for ICH elicited by the VAS 
 
 





Figure A5.14 Utilities for ICH elicited by the SG 
 
 




Figure A5.15 Utilities for major ECH elicited by the VAS 
 
 





Figure A5.16 Utilities for major ECH elicited by the SG 
 
 





Figure A5.17 Utilities for minor ECH elicited by the VAS 
 
 





Figure A5.18 Utilities for minor ECH elicited by the SG 
 
 




Figure A5.19 Utilities for MI elicited by the VAS 
 
 





Figure A5.20 Utilities for MI elicited by the SG 
 
 




Figure A5.21 Utilities for current health state elicited by the VAS 
 
 




Figure A5.22 Utilities for current health state elicited by the SG 
 
 
Std. Dev. = standard deviation, SG = standard gamble.  
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Appendix 6.1 Collection Form of Cost Data for Chapter 6 




Average frequency per 
month 
Warfarin per dose   
Dabigatran per tablet   
Rivaroxaban per tablet   
INR test   
Full blood count and creatinine 
clearance tests 
  
Physician consultation   
Pharmacist consultation   
One-time costs of complications (SGDs per event) 
 mean 10th to 90th percentiles 
Major ischemic stroke   
Minor ischemic stroke   
TIA   
ICH   
Major ECH   
Minor ECH   
MI   




Average frequency per 
month 
   
ECH = extracranial hemorrhage, ICH = intracranial hemorrhage, INR = International 
Normalized Ratio, MI = myocardial infarction, SGD = Singapore dollar, TIA = 
transient ischemic attack. 
 
